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Zusammenfassung 
DNS-Reparaturmechanismen sind essentiell, um die genomische Stabilität aufrecht zu 
erhalten und dadurch auch um Krebs entgegenzuwirken. DNS Interstrangvernetzungen 
(ICLs), die beide DNS-Stränge kovalent miteinander verbinden, gehören zu den 
gefährlichsten DNS Schäden, da sie sowohl die Transkription als auch die Replikation 
blockieren. In höheren Eukaryoten werden ICLs auf eine komplizierte Art und Weise repariert 
und viele verschiedene DNS-Reparaturmechanismen sind daran beteiligt, wie 
Transläsionssynthese (TLS), Nukleotidexzisionsreparatur (NER) und homologe 
Rekombination (HR). Proteine der Fanconi-Anämie Komplementationsgruppe werden für die 
Koordination der Reparatur benötigt. Patienten mit Mutationen in Genen, welche für diese 
Proteine kodieren leiden an der schwerwiegenden, genetischen Krankheit Fanconi-Anämie. 
Der ICL-Reparaturweg beginnt mit dem Aushaken der Vernetzung nachdem eine 
Replikationsgabel davor stecken geblieben ist, wobei Nukleasen auf beiden Seiten davon 
einschneiden um sie zu entfernen.  
FAN1 (FANCD2-associated nuclease 1) wurde in vier unabhängigen Forschungsgruppen als 
ein wichtiges Protein für die Reparatur von ICLs identifiziert. Es verleiht Zellen Resistenz 
gegen ICL-induzierende Chemikalien, wie zum Beispiel MMC (Mitomycin C) und Cisplatin. Mit 
Hilfe von in vitro Versuchen wurde gezeigt, dass FAN1 sowohl eine Endo- als auch eine 
Exonuklease-Aktivität besitzt. Als Endonuklease schneidet es präferentiell sogenannte 5' 
Flap-Strukturen. Die Exonuklease-Aktivität von FAN1 zeigt eine 5’->3’ Orientierung auf.  
Mein Ziel war es, mehr über die Funktion von FAN1 im Zusammenhang mit der Reparatur 
von ICLs zu erfahren. Ich machte von synthetischer DNS mit ICLs Gebrauch, um zu sehen ob 
und wie FAN1 in der Lage ist DNS um die ICL herum abzubauen. Dadurch konnte ich zeigen, 
dass FAN1 tatsächlich die Vernetzung aushaken kann, indem es auf beiden Seiten, also 5' 
und 3' davon schneidet. Dies war nicht der Fall, als ich zwei andere Nukleasen mit ähnlichen 
Spezifitäten, EXO1 und FEN1, benutzte. Auch mit lebenden Zellen konnte ich zeigen, dass 
FAN1 involviert ist in der Induzierung von Doppelstrangbrüchen in Abhängigkeit von ICLs, 
was auch für eine Rolle im Aushakungsschritt spricht.  
FAN1 ist ein potentielles Tumor-Suppressor-Gen und ICL-induzierende Chemikalien werden 
oft in der Chemotherapie verwendet. Deshalb könnte mehr Wissen auf dem Gebiet potentiell 
die Krebstherapie vereinfachen. 
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Summary 
DNA repair mechanisms are essential to maintain genomic stability and therefore to prevent 
cancer. DNA interstrand cross-links (ICLs), which covalently link both strands of the DNA 
double helix, are among the most cytotoxic DNA lesions due to their potential to block both 
transcription and replication. In higher eukaryotes, ICLs are repaired in a complex manner, 
involving several different DNA repair mechanisms, such as translesion synthesis, nucleotide 
excision repair and homologous recombination. The repair is coordinated by proteins of the 
FA complementation group, which, when mutated, contribute to the severe genetic disorder 
Fanconi anemia. After replication fork stalling at the site of the cross-link, the first step of ICL 
repair consists of lesion unhooking, where nucleases cleave at both sides of the cross-link in 
order to remove it.  
FAN1 (FANCD2-associated nuclease 1), which was independently identified in four different 
studies, possesses a conserved role in ICL repair, conferring resistance towards ICL inducing 
agents such as MMC (mitomycin C) or cisplatin. In in vitro assays, FAN1 was shown to 
contain both endo- and exonuclease activities, the former exhibiting a preference for 5' flap 
DNA structures and the latter a 5’->3’ polarity. 
My aim was to elucidate the function of FAN1 in the context of ICL repair. Specifically, I made 
use of synthetic DNA structures containing ICLs to assess the ability of FAN1 to unhook and 
degrade DNA across an ICL. I could show that FAN1 indeed is able to unhook ICLs in vitro by 
making incisions both 5' and 3' of them. This was not the case when I used two other 
nucleases with similar substrate specificities, EXO1 and FEN1. Using living cells, I could 
further show that the induction of ICL-dependent double-strand breaks is dependent on 
FAN1, which is consistent with a role in unhooking.  
FAN1 is a potential tumor suppressor gene and ICL inducing agents are often used in cancer 
chemotherapy. Therefore, better understanding of ICL processing could eventually lead to 
improved treatments.   
1 Introduction  
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1 Introduction 
1.1 DNA damage and repair 
Our DNA is under constant attack of endogenous and exogenous agents that damage it in 
various ways (1). If the DNA is left unrepaired, this leads to mutations and eventually to the 
development of cancer. It can happen that genes important for the survival, proliferation 
capacity or growth of the cells are hyperactivated or that genes important to counteract these 
functions are by chance disrupted or downregulated. Furthermore, a gene modified by a point 
mutation can lead to gain of function of the gene product that can be beneficial for the survival 
of the cell and transform it in this way. These and other mechanisms ultimately lead to the 
formation of cancer, where cells start to proliferate in an uncontrolled fashion (2,3).  
 
Figure 1: DNA damage and repair. An overview of the different DNA damaging agents, their 
effects on the DNA and repair pathways. Figure adapted from (1). 
The cell has evolved many ways to counteract DNA damage and hence the formation of 
cancer. An important part consists of the DNA metabolic machineries that can repair DNA 
damage. There is a multitude of different DNA repair pathways, each specialized to deal with 
a particular type of damage (see Figure 1). These pathways include the repair of replicative 
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errors by proofreading of the polymerases (4) or by the replication-associated mismatch-
repair (MMR) machinery (5), direct reversal of the damage (6), base excision repair (BER) for 
the repair of damaged or missing bases (7), nucleotide excision repair (NER) for removing 
bulky adducts (8), non-homologous end joining (NHEJ) (9) and homologous recombination 
(HR) (10,11) for the repair of double-strand breaks (DSBs) and finally, the repair of interstrand 
cross-links (ICLs) by a special pathway involving several mechanisms (12). The basic steps in 
each DNA repair pathway are the recognition of the lesion, cleavages that are made in the 
DNA to remove the damage, re-filling of the resulting gap by polymerases and finally ligation 
to restore the genetic information. These basic steps are heavily adapted to the specific 
needs of each DNA repair pathway. 
It has to be mentioned, however, that in special cases, DNA damage can also be tolerated 
(13). These DNA damage tolerance (DDT) mechanisms include translesion synthesis (TLS) 
and template switching (14). 
1.2 Replication and replication stress 
1.2.1 Eukaryotic DNA replication 
The faithful replication of the genetic material during S (synthesis) phase of the cell cycle is a 
prerequisite for the cell division in M (mitosis) phase. Eukaryotic DNA replication originates 
from thousands of origins of replication in each cell division and proceeds in a bidirectional 
manner. Interestingly, not all origins of replication are activated at the same time and some of 
them are 'dormant', meaning that they are never used under normal conditions, but can be 
activated during stress. Origins of replication are activated in a three-step process, including 
the recognition of origins, the assembly of a pre-replication complex (in G (gap) 1 phase of 
the cell cycle) and activation of the pre-replication complex. This process is highly regulated 
through the cell cycle to prevent multiple rounds of replication during a single cycle. Due to 
the antiparallel nature of DNA (one strand being 5'->3' and the other one 3'->5') and the fact 
that DNA polymerases always synthesize DNA 5'->3', the two strands must be replicated in 
opposite directions at the replication fork (see Figure 2). As the replication machinery is 
coordinated in a way that both strands are synthesized at the same site, one strand, the 
leading strand, can be synthesized continuously, while the so-called lagging strand must be 
synthesized in a discontinuous manner, producing stretches of DNA of about 100 to 200 
bases, called Okazaki fragments. Owing to the asymmetric nature of DNA synthesis, the DNA 
has to be unwound ahead for the whole length of at least one Okazaki fragment before it can 
be used as a template for synthesis. This leads to a long stretch of single-stranded DNA 
(ssDNA) that is coated by the heterotrimeric complex replication protein A (RPA), important 
for the stabilization of the ssDNA and the prevention of secondary structures. An active 
replisome further contains the DNA polymerases Pol ε and Pol δ, which perform leading and 
lagging strand synthesis, respectively. However, DNA polymerases require a primer to begin 
synthesis and Pol α first acts as a primase, synthesizing a short stretch of RNA and about 10 
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to 20 deoxynucleotides (15). The RNA primer is later removed in a process called Okazaki 
fragment maturation. During replication, Pol δ displaces a stretch of the previous Okazaki 
fragment at each end of synthesis, creating a RNA-DNA single-stranded flap. Short flaps are 
cleaved off by FEN1 (flap endonuclease 1), a structure-specific nuclease, resulting in a nick, 
which can be sealed by Ligase I. The processing of longer flaps involves the action of DNA2 
(DNA replication ATP-dependent helicase/nuclease), which is able to cleave longer flaps that 
are covered with RPA and therefore refractory to FEN1 cleavage. DNA2 action leaves behind 
a shorter flap that can again be processed by FEN1. Recently, it has been shown that yeast 
Dna2 can by itself generate re-ligatable ends and cleaves off the flap completely in vitro (16). 
Furthermore, the replisome contains replication factors, one of which being RFC (replication 
factor C, clamp loader), a five-subunit complex responsible for loading proliferating cell 
nuclear antigen (PCNA) on the DNA, which in turn is important for the stable interaction of 
DNA polymerases with the template DNA and their processivity (15). The replicative helicase 
consists of the Cdc45-MCM-GINS complex (CMG) and unwinds the DNA in front of the DNA 
polymerases by the ATP-driven 3’->5’ helicase activity of the MCM2-7 hexamer (mini-
chromosome maintenance). CMG also has a central role in coupling the helicase activity with 
the leading and lagging strand polymerases, as 'running-off' of the helicase would lead to long 
stretches of vulnerable ssDNA. Furthermore, the replisome also associates with checkpoint 
proteins in order to survey the DNA replication accuracy (see below) (17).  
 Figure 2: The eukaryotic replisome 
complex. A schematic representation of 
the eukaryotic replication fork is shown 
including only the most important 
proteins. Figure adapted from (18). 
 
 
 
 
 
Pol δ and ε both contain a 3' exonuclease activity used for proofreading. The correct 
nucleotide is bound rapidly in the active center of the polymerase and the correctness is 
assessed by a conformational change in which tight contacts are made between the active 
site and the newly forming base pair. Only if the bound nucleotide is correct is the primer 
extended, otherwise the terminal mismatch hinders extension and the polymerase switches to 
the exonuclease complex to remove the wrong nucleotide. Nucleotide incorporation then 
resumes at the trimmed end. The replicative polymerases thus repetitively shuttle between a 
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polymerizing and editing mode, which is regulated by the (in)correctness of the incorporated 
nucleotide (19).  
1.2.2 Replication stress 
Replication stress can be defined as the slowing or stalling of replication forks and DNA 
synthesis. The sources and consequences of replication stress are very diverse, which makes 
it difficult to unambiguously characterize this condition. Sources of replication stress include 
nicks or ssDNA gaps that are left in the DNA as intermediates of DNA repair pathways. They 
can also result from topological release or arise spontaneously (20). Another important source 
of DNA replication stress are unrepaired DNA lesions, including abasic sites, pyrimidine 
dimers, alkylated bases, bulky adducts and cross-links. Such unrepaired lesions can be 
bypassed by the DDT pathway and be repaired during postreplicative repair (21). 
Furthermore, misincorporated ribonucleotides can cause replication stress, which are inserted 
into the DNA by the replicative polymerases Pol δ and Pol ε at a strikingly high rate. Those 
ribonucleotides can be removed from the DNA by RNase H2, together with FEN1 or EXO1 
(exonuclease 1) (22). Certain sequences, like trinucleotide repeats, repetitive sequences or 
those that can form secondary structures and G-quadruplexes are also hard to replicate and 
need to be resolved by helicases for efficient replication. The collision of transcription bubbles 
with replication forks is another issue for the replisome. The cell employs different strategies 
to overcome this problem, e.g. the release of transcribed mRNA to stop transcription when a 
replication fork arrives. Another important mechanism is the covering of new transcripts by 
RNA processing factors, which prevent the formation of RNA-DNA hybrids, the so-called R-
loops, that can also present a problem for replication. Topoisomerases and helicases can 
release the topological stress that arises through the vicinity of replication and transcription 
machineries and RNase H as well as RNA-DNA helicases can remove R-loops. Common 
fragile sites are regions in the genome that are prone to replication stress-induced DSBs, 
which might be due to a lack of replication origins in this region and the inability to rescue 
forks. Surprisingly, the breaks at such common fragile sites are not induced passively, but are 
a product of MUS81-catalyzed cleavage (23,24). In addition, when factors important for DNA 
replication are limited, this can slow down replication speed and lead to the accumulation of 
replication stress. Limitation in the nucleotide pool is for example an important source of 
replication stress and of cellular transformation (25). Replication stress can be induced by 
hydroxyurea (HU), which inhibits ribonucleotide reductase, leading to a decreased production 
of deoxyribonucleotides. Aphidicolin (APH) is another drug commonly used to actively induce 
replication stress, as it inhibits the replicative polymerases. 
The persistence of ssDNA, bound by RPA and adjacent to double stranded DNA (dsDNA), 
also initiates the replication-stress response. The role of this signaling cascade is to arrest the 
cell cycle to allow time for repair and prevent the cell from entering mitosis. The so-called 
checkpoint factors also directly stabilize replication fork structures and facilitate DNA repair. 
Checkpoint signaling is activated after DNA damage or replication stress. Two main kinases 
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initiate this complex network: ATM (Ataxia telangiectasia mutated) and ATR (Ataxia 
telangiectasia and Rad3 related), which belong to the PIKK (phosphatidylinositol-3-kinase 
related kinases) family. These two kinases preferentially phosphorylate their targets at SQ/ST 
motifs (26). ATM is mainly responsible for the checkpoint response after DSBs, while ATR, 
together with its partner ATRIP (ATR-interacting protein), is activated through stretches of 
ssDNA covered by RPA. However, as ssDNA always exists at unperturbed replication forks 
on the lagging strand, it is important that ATR distinguishes those from stressed replication 
forks. This is mainly done by the 9-1-1 (Rad9-Hus1-Rad1) heterotrimeric clamp and its loader 
RFCRad17. They recognize the damaged DNA and facilitate the interaction between ATR-
ATRIP and checkpoint mediators (i.e. TopBP1 and Mrc1/Claspin), leading to the 
phosphorylation of checkpoint kinase 1 (Chk1), the major downstream checkpoint effector 
kinase (15).  
1.2.3 Recovery of stalled replication forks 
There are different ways how a damaged or stalled replication fork can resume synthesis 
(27). The easiest way to restart replication beyond a lesion is in the case of a lagging-strand 
template lesion, where the next Okazaki fragment can simply reprime downstream of the 
damage. However, even on the leading strand it is possible to continue DNA synthesis 
downstream of the damage by repriming, leaving behind a ssDNA gap that is repaired 
postreplicatively (28). This means that both, leading and lagging strand synthesis can be 
discontinuous. Alternatively, dormant origins can be activated so that replication is completed 
by the new replication fork arriving from the other side. Another way to continue DNA 
synthesis downstream of the lesion without leaving a ssDNA gap behind is by using TLS 
polymerases, which are able to bypass the damage so that accurate synthesis can continue. 
Indeed, also in the case of replication fork recovery by repriming, the remaining stretch of 
ssDNA can be filled-in by TLS polymerases or by template switching.  
One of the major sources of genome instability in eukaryotic cells is the collapse of stalled 
replication forks, leading to the formation of DSBs. If lagging strand synthesis continues once 
the leading strand is blocked at the site of a lesion, this can result in the uncoupling of the 
replicative helicase from leading strand synthesis and hence a large stretch of ssDNA will be 
left behind. This ssDNA is vulnerable and can lead to fork collapse, either passively or 
actively by endo- or exonuclease mediated cleavage (29). The breaks resulting from 
replication fork collapse are repaired by HR (see below, chapter 1.3.6), allowing for 
recombination-mediated fork restart. 
If direct replication fork restart by the activation of dormant origins or repriming fails, there is 
another way of rescuing stalled replication forks without the need for recombinational repair. 
This pathway involves complex replication fork remodeling by the regression of the replication 
fork and re-annealing of the template as well as the newly synthesized strands (30). These 
reversed forks can be restarted by exonucleolytic degradation by DNA2, reverse branch 
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migration catalyzed by the annealing helicase SMARCAL1 (SWI/SNF-related matrix-
associated actin-dependent regulator of chromatin subfamily A-like protein 1), or by HR 
(31,32). The so-called chicken-foot structure that is formed during fork reversal allows the 
lesion to be repaired by NER, as it is returned to a region of dsDNA. Alternatively, the newly 
synthesized lagging strand that now anneals with the nascent leading strand can act as a 
template for DNA synthesis across the site of damage as during template switching. In that 
case, after reverse branch migration by SMARCAL1, the lesion has to be repaired in a post-
replicative manner.  
1.3 Interstrand cross-link repair (ICL repair) 
1.3.1 Overview of the ICL repair pathway 
ICLs are covalent linkages between the two DNA strands and are very cytotoxic as they 
impede almost all DNA metabolic processes. The repair of ICLs requires the action of multiple 
DNA repair pathways (see Figure 3). The coordination of repair happens through the so-
called Fanconi anemia (FA) pathway, which recognizes the lesion during S-phase when the 
replication fork(s) are blocked at the site of the lesion. There is, however evidence for S-
phase independent ICL repair in mammalian cells (see chapter 1.3.10). Incisions around the 
lesion allow for ICL unhooking, releasing it from one of the two strands and results in the 
formation of a DSB due to the present stalled replication fork. TLS restores the DNA template, 
which can be used during HR to complete the process by repairing the DSB. The remaining 
adduct coming from the unhooked ICL may eventually be repaired by NER. In replication-
independent ICL repair, NER and TLS pols play a major role. Here, I shall discuss the 
complex mechanism of ICL repair, starting with a description of ICLs and the drugs 
generating them. I shall then introduce each of the mentioned processes in more detail and 
finally elaborate on ICL repair in different contexts. My focus will be on mammalian ICL repair 
and specifically on the protein I've been working with, FAN1 (FANCD2-associated nuclease 
1). 
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Figure 3: Overview of the ICL repair 
pathway. After stalling of one or maybe 
two replication forks at the ICL (red), 
one is extended (blue) to the site of the 
ICL for nucleolytic incisions (orange 
arrows) to be made in the unhooking 
step. TLS polymerases refill the 
resulting gap (purple) and HR is used to 
repair the DSB formed during 
unhooking. NER probably removes the 
remaining adduct and the DNA repair 
process is completed. 
 
 
 
 
 
 
 
 
 
  
1.3.2 Types of ICL inducing agents 
ICL agents can be of exogenous or endogenous origins and in general are alkylating agents 
with two reactive groups. One difficulty in studying the complex repair pathway that takes care 
of ICLs comes from the vast variety of ICLs formed by diverse agents that can elicit distinctive 
responses in the cell. Outcomes like sensitivity, cell cycle arrest or repair pathway choice can 
vary depending on the drug used (33). Therefore, and together with the fact that pathway 
choice and response also depend on the model system used, it is almost impossible to define 
a single ICL repair pathway and one has to be aware that sometimes a particular finding 
cannot be applied in a general context.  
Mustard gas (or sulphur mustard) reached tragic popularity during the Second World War, 
when a secret cargo of mustard gas bombs was destroyed at the air raid on Bari. Several 
hundred soldiers and civilians were affected and examination of the survivors showed a 
decreased number of lymphocytes. Exposure to mustard gas often resulted in slow and 
painful death, causing severe skin oedema and ulceration, blindness and suffocation. 
Unexpectedly, research with this compound resulted in the first chemotherapeutic agent. 
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Clinically used nitrogen mustards (NMs; derivatives of mustard gas) include 
cyclophosphamide and chlorambucil for the treatment of leukemia, melphalan for myeloma 
and ifosfamide for the treatment of testicular, breast and lung cancer (34). About 5% of the 
DNA damage caused by (NMs) are ICLs, while monoadducts and protein DNA cross-links 
constitute the majority of the products. The ICLs are mainly formed between the N7 atoms of 
guanines within GNC sequences. NM-derived ICLs are highly DNA distorting and relatively 
unstable (33). 
Other ICL agents include nitrosoureas (like BCNU, CCNU or methyl-CCNU), platinum 
compounds (like cisplatin), diepoxybutane (DEB), mitomycin C (MMC), or psoralens that are 
activated by UVA light. MMC and psoralens are both natural-occurring sources of ICL agents 
(33,35).  
ICL agents can also be produced endogenously in the cell. Aldehydes like malondialdehyde, 
formaldehyde, acetaldehyde, unsaturated aldehydes (acrolein, crotonaldehydes) or nitrous 
acid are all endogenous sources of ICL damage (12,35). Aldehydes are byproducts of 
metabolic pathways, like lipid peroxidation and alcohol metabolism and are found in certain 
foods or tobacco smoke. Nitrous acid is a byproduct of the metabolism of nitrite-containing 
food preservatives (34). 
DNA containing synthetic ICLs is an important tool to study those lesions in vitro. First 
attempts to obtain cross-linked DNA were based on the treatment of DNA with ICL inducing 
agents and purification of the desired products. However, as these reactions usually yield 
more intrastrand cross-links and monoadducts and only a minor fraction consists of ICLs, this 
approach was not very efficient. The new strategies for the synthesis of cross-linked DNA 
include the cross-linking of two nucleosides outside DNA before extending them into an 
oligonucleotide or the introduction of ICL precursors into two separate DNA molecules, which 
can, after annealing of the two strands, be activated to form the ICL (35). One such strategy is 
to incorporate 7-deazaguanine residues bearing acetaldehyde groups on opposing DNA 
strands and the induction of major groove NM-like cross-links by double reductive amination 
(36).  
1.3.3 Fanconi anemia proteins and pathway 
Fanconi anemia (FA) is a rare genetic disease characterized by bone marrow failure, 
congenital abnormalities, predisposition to solid and hematological tumors and 
hypersensitivity to cross-linking agents (37). The hypersensitivity towards DEB, with a 
dramatic increase in chromosome aberrations and quadradials is hence widely used as a 
diagnostic test for FA. FA is caused by mutations in one of at least 19 different genes, forming 
the FA complementation group (FANC-A to FANC-T), which all function in the repair of ICLs 
(see Figure 4 and Table 1) (38-40).  The most commonly mutated gene in patients is 
FANCA, followed by FANCC and FANCG (38).  
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Figure 4: The FA pathway. The FA pathway starts with the recruitment of the FA core 
complex by FANCM and the unloading of the CMG complex. Ubiquitination of the FA ID2 
complex then leads to nucleolytic incisions to unhook the ICL. TLS pols then re-fill the gap 
and HR repairs the DSBs that resulted from the unhooking step (FA effector proteins). FANC 
proteins are depicted in colors, while associated proteins, for which no FA patient mutations 
have been found, are shown in grey. Figure adapted from (39). 
After the formation of ICLs, DNA replication stalls at the site of the lesion during S phase of 
the cell cycle. The FA pathway is then initiated by FANCS/BRCA1 (breast cancer 1), which, 
together with its partner BARD1 (BRCA1 associated RING domain), unloads the replicative 
CMG helicase from the stalled replication fork (41). However, patients with FANCS/BRCA1 
mutations do not show bone marrow failure and therefore suffer from the so-called FA-like 
syndrome. FANCS/BRCA1 also has a much better known function downstream in the ICL 
repair pathway, namely in HR (see below, chapter 1.3.6). ICL recognition then requires 
FANCM (a DNA translocase and ATPase with branch migration activity), together with its 
partners FAAP24 (FA-associated protein 24kDa), MHF1 and MHF2 (histone fold protein 1 
and 2), which are members of the FA associated proteins (42-44). This leads to the 
recruitment and assembly of the FA core complex (FANCA, B, C, E, F, G, L, M and T) 
(42,45). FANCM has additional functions in the activation of cell cycle checkpoints through 
ATR-Chk1 signaling (46). This signaling cascade also leads to the phosphorylation of multiple 
FA core complex factors, including FANCA, E, D2, and I (47). FANCM associates with 
chromatin throughout the cell cycle and it contains, in addition to its helicase domain, a 
degenerate ERCC4-like nuclease domain, which is required for the interaction with FAAP24. 
After recruitment of the core complex to the site of the cross-link, FANCL (a RING domain-
containing E3 ubiquitin ligase), together with FANCT/UBE2T (an ubiquitin-conjugating 
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enzyme) (40), monoubiquitinates the FANCD2-FANCI complex (ID2) on both subunits (39). 
ID2 complex ubiquitination presumably stabilizes the complex binding to chromatin and is 
important for the coordination of the downstream steps, like nucleolytic incisions and 
translesion synthesis (48). USP1 is the responsible deubiquitinase for ID2 and this step is 
also essential for ICL repair. The ubiquitinated form of the ID2 complex acts as a landing pad 
for FAN1 and FANCP/SLX4, which both contain UBZ4 (ubiquitin-binding zinc finger 4) 
domains that specifically recognize the ubiquitin moiety of FANCD2 (47). FANCP/SLX4 in turn 
is a scaffold protein, recruiting several structure-specific nucleases, such as SLX1, MUS81-
EME1 and XPF-ERCC1 (49). One or several of these endonucleases then perform the 
unhooking reaction. Unhooking leads to a suitable substrate for TLS polymerases to repair 
one strand but so far no mutation of a TLS pol gene has been associated with FA. HR repairs 
the remaining DSB coming from initial incisions. Indeed, the other FA proteins are all 
implicated in HR (i.e. FANCD1/BRCA2, FANCJ/BRIP1, FANCN/PALB2, FANCO/RAD51C, 
FANCR/RAD51 and FANCS/BRCA1) by facilitating RAD51 loading or the resolution of 
recombination intermediates.  
 
Table 1: The Fanconi anemia complementation group. 
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1.3.4 Unhooking step in ICL repair 
Even though unhooking does not remove the ICL completely, it allows bypass of the lesion by 
polymerases. Five different nucleases have been implicated in the unhooking step: XPF-
ERCC1, MUS81-EME1, SLX1-SLX4, SNM1A and FAN1. FAN1 will be introduced separately 
in chapter 1.5. 
General features of nucleases 
Nucleases are molecular scissors that catalyze the cleavage of DNA or RNA between the 
sugar and the phosphate moieties of the backbone. They can be generally divided into 
exonucleases, which hydrolyze from the 5' or 3' end of nucleic acids, and endonucleases, 
which don't need a free end and hydrolyze internal phosphodiester bonds. However, the 
fundamental chemistry of endo- and exonucleases is the same and it is not uncommon that a 
single enzyme possesses both activities, mostly even using the same active site. The 
cleavage products of nucleases contain a 5' terminal phosphate group on one hand and a 3' 
terminal hydroxyl group on the other one. Virtually all DNA metabolic and repair pathways rely 
on DNA nucleases, with a few exceptions in the case of direct damage reversal. Moreover, 
many nucleases can act in more than one DNA repair pathway and a given cleavage reaction 
can usually be performed by multiple nucleases. This is what makes the study and 
understanding of these nucleases so challenging. DNA endonucleases can further be 
distinguished into sequence- damage- or structure-specific. Sequence-specific 
endonucleases are mainly known from prokaryotes, like restriction enzymes and the 
mismatch repair protein MutH. One example of eukaryotic sequence-specific endonucleases 
is I-SceI, which is expressed in the mitochondria of S. cerevisiae (50). Examples for damage-
specific nucleases in mammalian cells are the apurinic/apyrimidinic (AP) endonucleases used 
in BER to cleave 5' from an abasic site (51). Structure-specific endonucleases recognize 
intermediates of DNA repair that have specific structures. An example are the NER enzymes 
XPF and XPG, which cleave at the base of a bubble structure that surrounds the DNA 
damage after unwinding. DNA nucleases are usually two-metal-ion-dependent, but there are 
also some that depend only on one metal ion, like the type II restriction enzyme nucleases, 
and some even do not need a metal ion for catalytic activity, like DNAse II (51). In most cases 
Mg2+ is the metal ion needed for catalysis and Ca2+ usually inhibits the reactions. Mn2+ can 
often also be used; it usually relaxes the specificity towards substrates and sometimes can 
even rescue defective enzymes (52). The most frequent use of Mg2+ could be due to its high 
abundance in living organisms, its solubility, redox stability, small size and rigid coordination 
geometry compared to other divalent metals (51). For the general reaction mechanism of two-
metal-ion-dependent nucleases, see Figure 5. 
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Figure 5: Reaction mechanism of nucleases. A) A nucleophilic attack by a deprotonated 
water molecule (the oxygen of which is shown in blue) leads to the pentavalent transition 
state. The P-O3’ bond is then cleaved to generate a 5’-phosphate and a 3’-OH product. B) In 
the two-metal-ion-dependent enzymes, one of the oxygens coordinates both metal ions (Sp) 
and the A ion drives the reaction by deprotonating the nucleophilic water molecule (shown in 
blue). The B ion is used to stabilize the pentavalent transition state and to destabilize the 
ground state of the scissile phosphate for cleavage. Figure adapted from (51). 
It is very difficult to classify nucleases, as their sequence, structure, reaction mechanism, or 
function usually don't correlate, which would result in different categories depending on the 
criteria used. Usually, nuclease families are defined according to the secondary structure of 
their nuclease domains or sequences of active-site motifs, as their function or tertiary 
structure are not always known. 
XPF-ERCC1 
XPF-ERCC1 (Xeroderma pigmentosum complementation group F- Excision repair cross-
complementation group 1) is best known for its function in NER. The two subunits contain the 
same domains (a ERCC4 endonuclease domain and a Helix-hairpin-Helix (HhH) DNA binding 
domain) but the ERCC4 endonuclease domain is degenerate in ERCC1, rendering it 
catalytically inactive (53). XPF-ERCC1 preferentially cleaves splayed arm, bubble and 
stem‐loop structures with a 3' flap polarity and cleavage occurs on dsDNA regions close to 
the ssDNA. It has a specific role in ICL repair independently of the NER pathway and cells 
deficient in XPF-ERCC1 are more sensitive to ICL inducing agents than cells defective for 
other NER proteins (54). Biochemically, XPF-ERCC1 was shown to be able to unhook 
psoralen ICLs in vitro (55). Indeed, XPF mutations were also found in FA patients, suggesting 
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that it works in an FA-dependent ICL repair pathway and giving it the alternative name 
FANCQ. XPF-depleted Xenopus egg extracts are not able to perform the initial incision, 
further indicating a role for this protein in unhooking. Interestingly, in this system both 
cleavages 5' and 3' of the ICL were defective, indicating that the first incision by XPF is 
needed for the second one to occur, or that XPF is itself able to perform both incisions. The 
unhooking activity of XPF-ERCC1 was further stimulated by SLX4 (56). In mammalian cells, it 
was shown that ICL-dependent DSBs still form and even persist in the absence of XPF-
ERCC1 (54,57). This would be contradictory to a function in ICL unhooking. However, it might 
be reconciled with the fact that those stalled forks persisting in the absence of XPF-ERCC1 
are aberrantly cleaved by MUS81 (58). Furthermore, it is unclear how the 3' flap 
endonuclease activity of XPF-ERCC1 might perform both cleavages in unhooking. Therefore, 
although XPF-ERCC1 is commonly accepted to be the main ICL unhooking enzyme, further 
studies are needed to elucidate its exact mode of action. 
MUS81-EME1 
MUS81-EME1 (Methansulfonate and Ultraviolet-Sensitive 81- Essential Meiotic structure-
specific Endonuclease 1) belongs to the same nuclease family as XPF, with MUS81 being the 
catalytically active subunit. MUS81 is also a 3' flap endonuclease, but, in contrast to XPF, it 
prefers substrates where there is a 5' end close to the dsDNA-ssDNA junction (53). MUS81-
EME1 has been implicated in ICL unhooking due to its importance for ICL resistance and the 
DSB reduction upon depletion of the protein (58,59). However, those cells are less sensitive 
to ICL agents than XPF-ERCC1 lacking cells and in the Xenopus egg extract system 
depletion of MUS81-EME1 did not have an effect on ICL unhooking (56). This suggests that it 
acts only in a subset of cases, potentially when XPF-ERCC1 cleavage cannot occur due to a 
5' end close to the junction of the stalled replication fork(s). 
SLX1-SLX4 
SLX1 (structure-specific endonuclease subunit SLX1) contains a UvrC-intron-endonuclease 
domain (URI) and a PHD-type zinc finger domain and its preferred substrate is a 5' flap, 
which it cuts at the flap junction (60). SLX1's activity is drastically increased upon interaction 
with SLX4. SLX1 was proposed to be the main 5' flap endonuclease required for unhooking, 
as deletion of the gene causes ICL sensitivity, similar to that of MUS81 (61). 
SLX4 (structure-specific endonuclease subunit SLX4) is a Fanconi anemia protein (FANCP) 
and deletion of SLX4 causes much greater sensitivity to ICLs than the depletion of SLX1 or 
MUS81 (56,61,62). It is also required for incisions in the Xenopus egg extract system (56). 
This suggests that SLX4 is an important scaffolding protein, coordinating the different 
nucleases - XPF, MUS81 and SLX1 - to the site of the cross-link. Interactions of SLX4 with 
XPF-ERCC1 and SLX1 are important for ICL repair, while the interaction with MUS81 is 
dispensable (61,62). As mentioned above, SLX4 contains a UBZ domain that is important for 
its recruitment to monoubiquitinated FANCD2 at the site of the ICL (49). 
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SNM1A 
In vertebrates there are three proteins related to yeast Pso2/Snm1 in vertebrates: SNM1A 
(Sensitive to Nitrogen Mustard 1A), SNM1B/Apollo, and SNM1C/Artemis. They belong to the 
β-CASP subfamily of metallo-β-lactamases, which are all DNA processing enzymes (63). 
SNM1A is structurally most similar to Pso2, which made it the primary candidate for the 
vertebrate ortholog of Pso2, an endo- and exonuclease that has a specific function in ICL 
repair. SNM1C plays an important role in the DSB repair subpathway NHEJ and has so far 
not been implicated in ICL repair. SNM1B, which has functions in checkpoint signaling and 
telomere maintenance, could potentially act in ICL repair, as cells depleted of it are sensitive 
to ICL inducing agents (64,65). Human SNM1A and SNM1B are 5’->3’ exonucleases, while 
SNM1C is a structure-specific endonuclease (66,67). SNM1A has a stronger affinity for 
single-stranded DNA over double-stranded DNA, which is not the case for SNM1B. SNM1A is 
also more active on high molecular weight DNA compared to SNM1B and even though both 
proteins are able to digest DNA past an ICL that is induced by the agent SJG-136, SNM1A 
has a greater capacity to do so (67). Therefore, its proposed role in ICL repair is to trim back 
the DNA around the ICL that might be remaining after unhooking and it seems to do so in a 
common pathway with XPF-ERCC1 (58). As predicted, SNM1A is able to rescue the 
sensitivity in Pso2 yeast mutants, which was not the case for SNM1B or SNM1C (68). This 
suggests that SNM1A is the functional ortholog of yeast Pso2. However, SNM1B might have 
a partially redundant function, as double disruption of the two genes is additive in terms of 
cisplatin sensitivity compared to the single disruptants in DT40 chicken cells (69). 
SNM1A is recruited to the site of the ICL by RAD18-dependent ubiquitinated PCNA via its 
UBZ domain and PIP (PCNA interacting peptide) box (70). Just recently, the crystal structures 
of SNM1A and SNM1B/Apollo were resolved and a region of positive charge was found to 
surround the active site of SNM1A, which is absent in SNM1B/Apollo. This, together with a 
putative wide DNA-binding groove helps to explain the ability of SNM1A to accommodate and 
process highly distorted DNA structures (71).  
1.3.5 Translesion polymerases and their roles in ICL repair 
Translesion polymerases (TLS pols) are part of the DDT mechanism, also known as DNA 
damage bypass or post-replicative repair, where DNA replication is completed before the 
lesion is repaired. The repair then happens later in a post-replicative manner. There are two 
main ways of circumventing damage during replication, one are the TLS pols and the other 
one is template switching, in which the stalled nascent strand switches temporarily and uses 
the newly-synthesized strand of the sister chromatid as a template for synthesis past the 
lesion. Once it switches back to its original template, the newly synthesized strand is error-
free. This is different in the case of specialized polymerases, which bypass the damaged 
base that would otherwise block the progression of the replication fork with the cost of being 
error-prone. TLS pols have different substrate specificities, enabling them to deal with 
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different types of damaged bases. The polymerase switch from replicative to TLS pols is 
mainly coordinated by PCNA ubiquitination upon fork stalling. The interaction between the 
ubiquitin moiety on K164 of PCNA and ubiquitin binding motifs on TLS pols ensures the 
recruitment of TLS pols to the stalled fork. Following the first polymerase switch, nucleotide 
insertion across the lesion and extension past the lesion may require the concerted action of 
more than one TLS pol and, once the lesion is bypassed, a further polymerase switch has to 
occur to reposition the replicative polymerase at the primer terminus and for accurate DNA 
synthesis to resume (72).  
Based on sequence and structural similarities, human pols can be grouped into five different 
families: A, B, X and Y and the reverse transcriptase activity of telomerase. The common 
feature of all pols is that they fold into a structure that resembles a human right hand 
composed of three distinct domains, the palm, thumb, and fingers. In contrast to the 
replicative polymerases, TLS pols have a low fidelity in nucleotide incorporation and 
additionally lack the proofreading activity, making them error-prone. Whereas the fingers in 
replicative pols tightly bind the incoming dNTP, the active site of TLS pols is more open and 
less constrained to reject wrong base pairs. However, there are a few examples, as for Pol η 
with TT-CPDs (cyclobutane pyrimidine dimers), where the bypass of lesions can be error-free. 
The replicative pols α, δ and ε belong to the B family and the mitochondrial pol γ to family A. 
Several TLS pols have been implicated in ICL repair, such as the Y family pols η, κ, and 
Rev1, the B family pol ζ, the A family pol ν and sometimes θ.  
As mentioned before, Pol η, also called XPV, is responsible for the bypass of UV-induced 
CPDs. However, it also has important functions in ICL repair, highlighted by the fact that XPV 
patient-derived cell lines are highly sensitive to cross-linking agents (73,74). Pol η may also 
have a role in replication-independent ICL repair, as shown by a plasmid-based host-cell 
reactivation assay (75). Pol η is able to bypass synthetic, structurally distinct ICLs also in 
vitro, which becomes more efficient when using longer ICLs and a shorter DNA fragment 
surrounding the ICL opposite the template strand, both probably due to an easier 
displacement of the non-template strand (76). 
Pol κ is the most accurate Y family polymerase on undamaged DNA and has a role in NER in 
the repair synthesis step together with Pol δ (77). Also Pol κ could potentially be involved in 
ICL repair, as human cells depleted of the protein are hypersensitive to MMC and it is able to 
fulfill ICL bypass in vitro (76,78).  
Pol ζ is a heterodimeric protein, consisting of the catalytic subunit REV3 and the structural 
subunit REV7. Pol ζ is thought to be the major contributor to TLS over lesions. Its efficiency of 
lesion bypass is enhanced by REV1 and PCNA (79). Pol ζ has been implicated in ICL repair, 
as cells deficient for REV3 or REV7 are exquisitely sensitive to ICL inducing agents and in 
chicken cells the sensitivity was even greater than the one for FANCC (80). Also 
biochemically, (truncated) Pol ζ is able to bypass ICL lesions, in conjunction with Pol η (81). 
REV1 is not a real polymerase, having a template-directed deoxycytidyltransferase activity, 
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mainly incorporating C opposite DNA lesions. REV1 binds monoubiquitinated PCNA via its 
ubiquitin binding motif (UBM) and can interact with several TLS polymerases including Pol η, 
ι, κ and ζ via its C-terminus. In addition, FAAP20, a component of the FA core complex, was 
shown to be required for the recruitment of REV1 to nuclear foci and this happens through a 
direct interaction between a UBZ4 domain of FAAP20 and the monoubiquitinated form of 
REV1 (82). An additional role for REV1 together with Pol ζ appears in replication-independent 
ICL repair (83). Furthermore, in X. laevis extracts REV1 inserted a cytosine opposite the 
unhooked ICL, which was followed by Pol ζ extension (84).  
Pol ν is also required for ICL repair, as evidenced by cellular sensitivity to cross-linking agents 
and its interaction with the ID2 complex. It further has a role in HR together with RAD51 and 
HELQ, a 3’->5’ helicase (85). Pol ν is error-prone, has a robust strand displacement activity 
and the ability to bypass thymine glycols and major groove ICLs in vitro (86,87).  
1.3.6 Homologous recombination and ICL repair 
Double strand breaks (DSBs) are very cytotoxic lesions, which is mainly reflected by the fact 
that already the presence of only a few DSBs in the cell can lead to cell death and 
chromosomal rearrangements. The rearrangements in turn can potentially inactivate tumor 
suppressor genes or lead to the overexpression of oncogenes thereby driving cancer 
formation. Therefore accurate and fast repair of such damage is crucial to the cell and three 
main pathways have evolved to take care of these lesions in mammalian cells: Non-
homologous end-joining (NHEJ), single-strand annealing (SSA) and homologous 
recombination (HR). HR is the most accurate mechanism, where the homologous sequence 
of the sister chromatid is used as a template for DNA synthesis, thereby restoring the missing 
DNA information. HR is however limited to the S and G2 phases of the cell cycle, as sister 
chromatids are only present then. In NHEJ on the other hand, the two termini of the broken 
DNA are processed, recessed and directly re-ligated, which can result in loss or gain of 
nucleotides, hence making it an error-prone mechanism of DSB repair. Moreover, if more 
than two free DNA ends exist in the cells, the wrong ones can be joined together, leading to 
chromosomal translocations. However, as NHEJ does not depend on homologous 
sequences, this pathway is preferably used during G1 and M phases of the cell cycle (88). 
The third pathway, SSA is even more inaccurate as it can lead to large deletions in the 
genome. It depends on direct repeats that are located close to the DSB, where extensive 
resection occurs in order for the two homologous sequences to anneal.  
Besides their main role in the repair of DSBs, HR proteins have many other functions, like in 
the repair of DNA cross-links, at damaged replication forks, during the segregation of 
homologous chromosomes in meiosis I and in telomere maintenance (89-91). Several genetic 
disorders are associated with HR dysfunction, such as Bloom's syndrom, Fanconi anemia 
and cancer types including breast, ovarian and others. The HR pathway is schematically 
depicted in Figure 6. A prerequisite for homologous DNA recognition is the formation of 
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ssDNA by DSB end resection. In human cells, resection is initiated by the MRN complex, 
consisting of MRE11, RAD50 and NBS1. MRN is a Mn2+-dependent exonuclease that resects 
DNA 3’->5’ and is regulated by CtIP (CtBP interacting protein) (92). As HR requires 3' 
overhangs in order to start invasion of the complementary sequence, the MRN polarity seems 
to be incompatible with this function. However, it was shown in yeast that the ortholog of 
MRN, MRX (Mre11-Rad50-Xrs2) contains an endonuclease activity, which requires activation 
by the CtIP ortholog Sae2 and Mg2+ (93). It can therefore incise the dsDNA distal to the DSB 
and then degrade it 3’->5’ until the DNA end to leave a 3' tail on the complementary strand 
(94). It is very likely that a similar mechanism exists in human cells, where CtIP could 
stimulate MRN endonuclease activity. MRN also has a role in sensing and signaling the DSB, 
leading to the activation of ATM, which in turn phosphorylates the histone variant H2AX on 
Serine 139 at the breakage site. This results in distinct γ-H2AX foci that are readily detectable 
by immunofluorescence (IF) (95). The short-range resection performed by MRN and CtIP is 
followed by a more extensive resection, executed by two different enzyme complexes. One is 
the BLM helicase together with the DNA2 nuclease. Although DNA2 also has helicase 
activity, this is dispensable for its function in DSB resection. RPA and the TOPOIIIα-RMI1-
RMI2 complex both stimulate the helicase activity of BLM and ensure 5’->3’ polarity of 
resection. The second pathway consists of EXO1 that is stimulated by BLM, MRN, RPA and 
CtIP (96,97). The 3' overhanging tails resulting from resection lead to the activation of ATR 
and are covered by RPA to eliminate secondary structures. In a next step, RAD51 is loaded 
onto the ssDNA to promote homologous DNA pairing and strand exchange in an ATP-
dependent reaction. RAD51 binding to the DNA requires several proteins, including BRCA2, 
RAD51 paralogs, PALB2 and RAD52. During the so-called synapsis, the RAD51 filament 
invades the undamaged strand to generate a displacement loop (D-loop), where it primes 
DNA synthesis and leads to the formation of a Holliday junction (HJ). From here on there are 
several HR subpathways, mainly the synthesis-dependent strand annealing (SDSA) and dHJ 
(double Holliday junction) pathways. SDSA involves the re-annealing of the extended strand 
with the original complementary 3' tail, where DNA synthesis proceeds and any remaining 
flaps are cleaved and the nick is ligated. The main outcomes are non-crossover products, 
which reduces the potential for genomic rearrangements and makes it the preferred HR 
pathway (98). The dHJ pathway involves second-end capture and, as the name suggests, 
formation of a double Holliday junction as shown in Figure 6. Three main classes of 
eukaryotic structure-selective endonucleases that can cleave HJ have been identified (99). As 
for human proteins, the XPF class is represented by XPF and MUS81, the UvrC/URI-YIG 
class by SLX1 and the Rad2/XPG class by GEN1 (53,100). Depending on the cleavage 
polarity of the HJ resolvases, the result can be a non-crossover or a cross-over product. 
Alternatively, dHJs can be dissolved by the RecQ-family helicase BLM together with 
TOPOIIIα-RMI1-RMI2, leading to non-crossover products (98).  
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Figure 6: The HR pathway. After recognition of the 
DSB, pathway choice is directed towards HR by 
inhibiting 53BP1. The DNA end is resected 5’-3’ by 
specialized nucleases, which leads to a 3’ overhang. 
Strand invasion, D-loop formation and second end 
capture lead to the formation of a double HJ, which 
can be resolved and the DNA is re-ligated. Figure 
adapted from (101). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the case of two replication forks stalling at the site of an ICL and unhooking (as shown in 
Figure 3 for example), the result is a two-ended DSB, which can be repaired as just 
mentioned. If only one replication fork stalls at the cross-link and unhooking takes place, it 
results in a one-ended DSB, which can be repaired by the HR-subpathway called break-
induced replication (BIR, shown in Figure 7). After resection of the free end, the 3' overhang 
can invade the other duplex and form a D-loop. As opposed to the other HR pathway, the 
newly synthesized strand does not have a complementary strand to re-anneal to. Therefore it 
continues replication until the end of the chromosome or the encounter with another 
replication fork. Lagging strand synthesis is re-established on the displaced DNA strand, 
resulting in a HJ that can be cleaved by HJ resolvases. Since BIR usually results in loss of 
heterozygosity (LOH), this pathway might be actively suppressed when the DSB contains two 
ends (102,103). 
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Figure 7: Repair of a one-
ended DSB. Upon 
resection, the overhanging 
3’ tail invades the sister 
chromatid and creates a D-
loop. Lagging strand 
synthesis resumes, which 
leads to the formation of a 
HJ that can be cleaved and 
the replication fork is 
restored. Figure adapted 
from (102). 
 
As HR mediated repair is mainly restricted to the S and G2 cell cycle phases, the expression 
of many HR factors is elevated in these cell cycle phases (104). A further control occurs via 
phosphorylation of important players, especially those involved in the decision-making step of 
DNA end resection, by CDKs (cyclin dependent kinases) (105). For example, CtIP 
phosphorylation, stability and BRCA1 interaction are regulated during the cell cycle, to ensure 
the correct repair pathway choice (106-108). BRCA1 and 53BP1 are the two critical 
components that compete with each other for pathway choice, where 53BP1 promotes NHEJ 
and BRCA1 commits cells to HR (104,109). BRCA1 inhibits 53BP1 and therefore NHEJ, 
which is evidenced by the fact that BRCA1-deficient phenotypes (resulting from error-prone 
NHEJ) can be alleviated by 53BP1 deletion (110,111). 
HR and ICL repair are tightly connected, which is mainly reflected by the fact that many of the 
FA proteins are actually known for their function in HR (BRCA2/FANCD1, PALB2/FANCN, 
BRIP1/FANCJ/BACH1, RAD51C/FANCO, RAD51/FANCR, BRCA1/FANCS). Furthermore, it 
was shown that patient-derived FANCA-, FANCG-, and FANCD2-deficient cells are slightly 
defective in HR repair (112) and that FANCC knockout DT40 cells are impaired in HR 
(113,114). On the other hand, the HR factor CtIP is recruited to sites of ICLs by FANCD2 and 
this complex plays an important role in the faithful repair of such lesions (115,116).  
Interestingly, it has been shown that the inhibition of the NHEJ pathway in human FA patient-
derived cell lines reduces the toxicity of ICL-inducing agents (117,118). The occurrence of 
radial chromosomes normally observed in FA cells was decreased upon inactivation of NHEJ 
pathway, indicating that NHEJ is responsible for these chromosomal aberrations and that the 
FA pathway is involved in the suppression of NHEJ during ICL repair to prevent the formation 
of such toxic genomic rearrangements. Furthermore, it shows that HR is still active in FA 
cells, but that the FA pathway either directly inhibits the NHEJ pathway or stabilizes a DNA 
structure that is more compatible with repair by HR than by NHEJ. Therefore, the toxicity 
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mainly comes from those genomic rearrangements caused by NHEJ and not from the inability 
to repair DSBs.  
1.3.7 Nucleotide excision repair and ICL repair 
NER is a highly versatile repair pathway, which takes care of different bulky, helix-distorting 
types of DNA lesions. UV lesions such as cyclobutane pyrimidine dimers (CPD) and 6‐4 
photoproducts are the most prominent modifications addressed by the NER pathway (119). 
NER additionally recognizes and repairs DNA lesions that are caused by chemicals that have 
the ability to covalently bind to one or two DNA bases, therefore forming bulky adducts and 
intra- or interstrand cross-links (120). The importance of NER is reflected by the severe 
genetic disorders that defects in NER cause, including Xeroderma pigmentosum, Cockayne’s 
syndrome (CS) and trichothiodystrophy (TTD), all of which are characterized by an extreme 
sensitivity towards UV light (120). In addition, deficiency of the NER protein XPF has only 
recently been linked to Fanconi anemia (121,122). 
Although not directly proven so far, it is thought that the remaining adduct on the DNA 
resulting from ICL unhooking is removed by nucleotide excision repair (NER). Furthermore, 
NER might have an important function in the removal of ICLs outside of S-phase (see below, 
chapter 1.3.10). XPF-ERCC1 depletion shows the highest sensitivity to ICL agents of the 
NER proteins, which is probably attributed to its independent role in ICL unhooking. However, 
also depletion of other NER proteins leads to sensitivity (54).  
NER can generally be broken down into five steps: damage recognition to initiate repair, helix 
opening and unwinding, incision on either side of the lesion to release the damage-containing 
oligonucleotide, DNA synthesis and ligation (Figure 8). Furthermore, NER can be divided into 
two distinct subpathways, termed global genome repair (GGR) and transcription-coupled 
repair (TCR). As the names suggest, the former is responsible for the repair of lesions in the 
entire genome and the latter repairs transcription-blocking lesions present in transcribed 
genes. These two subpathways differ in the way of damage recognition. In GGR the XPC-
HR23B (RAD23 homolog B) complex is the first NER factor to detect a lesion, whereas some 
less distorting lesions require initial recognition by the DDB1-DDB2 (damage-specific DNA 
binding protein 1 and 2) complex. In TCR, RNA polymerase II (RNAPII) is stalled by lesions in 
the transcribed strand of active genes and attracts NER enzymes, bypassing the need for 
XPC. CSA, CSB and XAB2 (XPA binding protein 2) are also specifically required for TCR. At 
this stage the two pathways converge, the TFIIH complex is recruited and immediately joined 
by XPA, RPA, and XPG. The XPB and XPD components of TFIIH are DNA helicases, and 
through their action TFIIH unwinds the DNA surrounding the lesion until a 30-nucleotide (nt) 
“bubble” is formed. RPA and XPA stabilize the DNA bubble and help to position two 
endonucleases at the bubble junctions. The first incision, on the 3′ side of the bubble relative 
to the lesion, is made by XPG, which also coordinates the second incision on the 5′ side of 
the bubble by the XPF protein and its partner ERCC1. A lesion‐containing DNA fragment of 
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25–32 nts is released, the gap is filled in by DNA pol δ, ε or κ using the information from the 
intact complementary strand and the final ligation step can be carried out by ligase I and 
FEN1 or by the ligase III–XRCC1 complex (120,123,124).  
 
Figure 8: The two NER subpathways. The lesion (depicted as a triangle) is recognized by 
XPC and HR23B in GGR and by RNAPII in TCR. After unwinding of the DNA around the 
lesion, the two pathways converge, leading to the incisions by the endonucleases XPF and 
XPG, whereafter the gap is refilled and the remaining nick religated. Refer to the text for more 
details. Figure adapted from (120). 
1.3.8 ICL repair in the Xenopus system 
To recapitulate ICL repair in a cell-free system, Räschle et al. first made use of Xenopus 
laevis egg extracts that support DNA replication of plasmids (84,125). To this end, High-
Speed Supernatant (HSS) of egg cytoplasm is added to the DNA, which leads to the 
assembly of the pre-RC. The subsequent addition of nucleoplasmic extract (NPE) leads to a 
single round of DNA synthesis. In their studies, they used a plasmid containing a single 
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sequence-specific cisplatin ICL. Using this system, they were able to identify several steps of 
ICL repair. First, two DNA replication forks converge on the lesion, where their leading 
strands stall 20 to 40 nts away from it. Recently, it could be shown that when only one fork 
reaches the ICL, the replicative CMG helicase is not unloaded from the stalled fork and the 
repair is blocked, meaning that two forks have to converge at the site of ICL for the repair to 
be initiated in this system (126). In another publication, they reported BRCA1 to be important 
for this helicase-unloading step (41). After helicase unloading and a delay of about 20 min, 
one leading strand approaches to within one nt of the ICL. This step is performed by 
replicative polymerases (127). After another delay of about 30 min, this is followed by dual 
incisions to uncouple the DNA strands, lesion bypass, and extension of the nascent strand 
beyond the lesion. In their system, depletion of XPF, but not of MUS81 or FAN1 lead to a 
defect in ICL repair and they could further show that XPF-ERCC1 together with SLX4/FANCP 
was able to perform the unhooking step. Furthermore, the ubiquitinated FANCD2 promoted 
the recruitment of SLX4 and XPF-ERCC1 to the ICL (56). The lesion bypass was then 
performed by a complex of REV1 and Pol ζ, which was stimulated by the FA core complex 
but not by ID2, and induced a short mutagenic tract (127). The Xenopus egg extract system 
has proven to be a powerful model for the study of replication-dependent repair. It has to be 
mentioned, however, that the existence of only one origin of replication on a relatively small 
DNA molecule is not equivalent with the situation in the mammalian cell. Furthermore, it 
cannot be excluded that the pathways for ICL repair differ in frog and man.  
1.3.9 Replication traverse of ICLs 
To test whether the model described for the Xenopus system also holds true for mammalian 
genomes, Huang et al. developed a single-molecule technique to assess the encounter of 
replication forks at ICLs in living cells (128). They used photoactivated psoralen as an ICL-
inducing agent, as it yields a high frequency of ICLs relative to monoadducts compared to 
other cross-linking drugs and because of the possibility to link psoralen to an antigen that can 
be later detected by IF (129). Their DNA fiber-based approach revealed that the major 
fraction of forks that stalled at the site of an ICL was consistent with replication on either side 
of the ICL linking the two parental strands. They could also show that the replication was 
continuous in over 50% of the cases, leading them to postulate a new way of replicating at an 
ICL being the traverse of such lesions. They also found about 20% of single-sided patterns 
(one fork stalled at the ICL) and a slightly lower amount of patterns that were in agreement 
with the dual fork collision model derived from the Xenopus egg extract system. This picture 
was the same in different cell lines tested and they could exclude the firing of dormant origins 
as a major contributor to this scheme. They calculated the time cost for replication on DNA 
with ICLs to be about 4.5 to 7 min depending on the cell line used. The time cost for 
replication over Angelicin (an equivalent of psoralen that can only form monoadducts) was 
only about 1 min. By using knock-out cell lines they could further show that the FANCM/MHF 
complex is important for the replication traverse of ICLs, where specifically their DNA binding 
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and translocase activities were needed. In contrast, neither the FA core complex, nor 
ubiquitinated FANCD2 were required for this process.  
1.3.10 Replication-independent ICL repair 
There is strong evidence that in mammalian cells ICL repair can happen in the absence of 
replication or recombination. First insights came from a site-specifically cross-linked reported 
plasmid that lacked an origin of replication. Therefore, ICL repair had to take place in a 
replication-independent manner (75). This pathway happens mainly in the G0/1 phase of the 
cell cycle and is dependent on NER proteins and TLS pols, particularly REV1 and Pol ζ 
(83,130,131). The repair of cisplatin ICLs was dependent on the TCR-NER specific protein 
CSB, suggesting that this is the preferred pathway for this type of damage, which is reflected 
also by the sensitivity of CSA and CSB cells to cisplatin (131,132). However, by looking at 
different types of ICL inducing agents, including MMC and psoralen/UVA, it becomes clear 
that probably both, TCR and GGR pathways play a role in the recognition and repair of all 
types of ICLs, but that some are preferably repaired by one pathway or the other depending 
on the structure (75,130,132-134). It is unclear what structural changes the GG-NER 
recognizes in the ICL. DDB1-DDB2, which is important for initial UV damage recognition and 
binds to these lesions, is not involved in the recognition of ICLs (130). An involvement of 
MMR proteins, such as MutSβ, in the replication-independent ICL repair pathway and 
specifically in the recognition step is also possible (135). ICL repair in G1 was independent of 
HR and RAD51, although some type of recombinational events occurred that was dependent 
on XPF in a cell-free cross-link repair synthesis assay (136). RPA and PCNA were also found 
to be required for the repair synthesis step as well as the TLS pols REV1 together with Pol ζ 
(131,137). A current model for mammalian G1 ICL repair suggests the recognition by GGR or 
TCR and a first round of unhooking the ICL by NER proteins, followed by TLS by REV1 and 
Pol ζ and finally another round of NER to remove the remnant of the ICL on the other strand 
(see Figure 9). It is unclear, however, whether the NER proteins fulfill the dual incisions to 
unhook the ICL alone or whether other proteins are also involved in this process 
(136,138,139). 
  
Figure 9: Replication-
independent ICL repair in 
mammalian cells. 
Replication-independent ICL 
recognition in mammalian cells 
has some parallels with the 
NER pathway and can also be 
initiated in a global or 
transcription-coupled way. 
After unhooking, TLS pols refill 
the gap and a second round of 
NER removes the remaining 
adduct. Figure modified from 
(140).
1.3.11 ICL repair by glycosylases 
Only recently, a novel DNA glycosylase from the bacterium Streptomyces sahachiroi was 
characterized, revealing some very interesting properties that could have tremendous impacts 
on the field of ICL repair (141). Azinomycin B is a novel ICL-inducing agent, leading to major 
groove ICLs at GNC or GNT sequences, isolated from S. sahachiroi and Streptomyces 
griseofuscus. Obviously, the producers have to protect themselves from the lethal effects of 
the drug. This is usually done by target site modifications, drug inactivation, drug binding or 
export (141). They identified Orf1 as an essential resistance protein against azinomycin B 
from the S. sahachiroi genome. Further characterization of the protein revealed that it binds to 
native DNA non sequence-specifically and interacts with an even greater affinity with 
azinomycin B-modified DNA. Further biochemical analysis showed that Orf1 could reverse the 
cross-links induced by azinomycin B, restoring the denaturation of the dsDNA under alkaline 
conditions. As no smaller DNA fragments were observed, the cleavage did not occur at the 
phosphodiester backbone. When the Orf1- dependent products were further incubated with 
Endonuclease IV (an apurinic/apyrimidinic (AP) endonuclease), this led to the degradation of 
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the DNA, indicating that Orf1 reverses the cross-link by depurination. Monoalkylated and 
interstrand cross-linked DNA molecules are both reversed by Orf1, which incised the 
adducted guanosines in both strands in the case of the ICL. If the two glycosidic incisions or 
the following AP endonuclease cleavages were temporally shifted, this pathway could even 
get around the formation of potentially toxic DSBs. This publication opened the possibility of a 
glycosylase-dependent ICL repair pathway, which might be similar to the BER pathway (see 
Figure 10). One problem with glycosylases regarding their usage in ICL repair is that they 
generally flip the damaged base out of the double helix and into their binding pocket for 
recognition and an ICL would be incompatible with base flipping. However, a recent 
publication shows the crystal structure of the first known DNA glycosylase that does not 
require base flipping for binding or excision, AlkB from Bacillus cereus (142). This further 
substantiates the probability of a glycosylase-dependent ICL repair pathway and it would be 
interesting to see whether Orf1 also works without base flipping, potentially by its crystal 
structure. It has to be seen whether an analogous pathway exists in mammalian cells, which 
is highly probable due to the simplicity of this type of pathway compared to, e.g. the FA 
pathway.
 
 
Figure 10: Potential BER-dependent ICL 
repair pathway identified in S. sahachiroi. 
Orf1, the newly identified glycosylase incises 
the glycosydic bond of the adducted 
guanines. An AP endonuclease cleaves at 
the resulting abasic site, leading to a nick 
that can be refilled by a polymerase before 
the DNA ligase restores the ds nature of the 
DNA. Figure taken from (141). 
 
1.3.12 ICL repair in yeast 
Most of the knowledge about ICL repair in yeast comes from genetic studies and, in 
accordance with the results from mammalian cells listed above, most of the mutants belong to 
one of the three pathways; NER, HR or TLS.  
The first incision at the ICL is made by the NER enzymes Rad1-Rad10, Rad2, and Rad3 
(homologs of human XPF-ERCC1, XPG and XPD). Rad1-Rad10 makes incisions 5' to the 
ICL, while Rad2 makes the incision 3' to it. ICL repair in yeast leads to a high amount of 
DSBs, which are then removed by HR. In yeast, all NER mutants are similarly sensitive to ICL 
agents, as opposed to mammalian cells, where XPF-ERCC1 seems to be exclusively 
important for the repair of ICLs (33).  
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As mentioned above, yeast have only one SNM1 gene (also called PSO2), compared to the 
three homologs in human. Pso2 deficient cells are exquisitely sensitive to ICL agents, 
suggesting that the protein does not have a role in another pathway. Pso2 has both, 5’->3’ 
exonuclease and structure-specific endonuclease activities and is thought to act downstream 
of the initial incisions controlled by NER (63). 
The only FANC core complex proteins that have homologs in S. cerevisiae are FANCM 
(Mph1) and FANCT. Other FANC proteins that have homologs in budding yeast are FANCJ 
(Chl1), FANCO (Rad51c), FANCP (Slx4), FANCQ/XPF (Rad1) and FANCR (Rad51) and the 
FANCM-associated factors MHF1 and MHF2 (Mhf1 and Mhf2). Interestingly, disruption of 
these FA-like genes in budding yeast did not sensitize them towards ICL agents, leading to 
the assumption that there is no FA or FA-like pathway in yeast. However, recently there have 
been two reports about the discovery of a FA-like pathway in budding yeast, which is S-phase 
dependent and plays a secondary role to the Pso2- and TLS-dependent pathway(s) (143-
146).  
In general, mammalian and yeast ICL repair are quite similar. The main differences are the 
involvement of FANC and BRCA proteins in mammals and the greater involvement of NER in 
yeast.  
1.4 FEN1 
As mentioned above in chapter 1.2.1, FEN1 (flap endonuclease 1) and DNA2 are the main 
nucleases responsible for flap removal during Okazaki fragment processing. In addition, 
FEN1 has a role in long-patch BER, where it cleaves flaps generated by Polβ's strand 
displacement activity. FEN1 is a metallonuclease, having a nuclease domain and an 
extended C-terminal region, which is important for interactions with PCNA and WRN 
(147,148). FEN1 preferably binds to a structure containing a 1-nt 3' flap and a 5' flap, which it 
recognizes at the base of the flaps (149). FEN1 then interacts with both dsDNA regions close 
to the flaps and bends the DNA at the site of the nick, where also the active site resides. Tight 
contacts with the 3' flap nucleotide by a hydrophobic wedge show the importance of this 
structure. The interactions with the 5' flap happen only at the base and DNA binding is then 
further stabilized by a threading mechanism, in which first the 5' end of the flap and then the 
entire flap passes through a gateway structure. Such a threading mechanism to select for flap 
structures is seen in other nucleases of the superfamily, such as XPG, GEN1 and EXO1. A 
cap structure, which is present only in EXO1 and FEN1, ensures that only ssDNA that 
contains an end passes through and leads to the selectivity (150). DNA2 recognizes ssDNA 
ends and uses a similar threading mechanism to directly displace RPA (151). 
Additionally, it has been shown that FEN1 possesses a gap endonuclease (GEN) activity, 
which allows it to cleave stalled replication fork-like structures or bubbles opposite a gap or 
anick. The cleavage activity was dependent on its interaction with WRN (152). The threading 
mechanism seems to contradict such a GEN activity as no free end is present in these 
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structures, but differential regulation on several levels might ensure the proper usage of 
different FEN1 activities during various DNA metabolic processes (152). 
In addition to its 5' flap and GEN activities, FEN1 possesses a 5’->3’ exonuclease activity on 
dsDNA, for which it needs an entry point, but it can also degrade blunt ended DNA, albeit less 
efficiently (153). The exonuclease activity has been associated with apoptotic DNA 
fragmentation and Okazaki fragment processing (153). 
FEN1 mutant MEFs (mouse embryonic fibroblasts) harboring a single mutation in the 
nuclease domain that abolishes the exonuclease and GEN but not the flap endonuclease 
activity (E160D) are sensitive towards the ICL inducing agent MMC (154). This could indicate 
that FEN1 is able to unhook or recover ICL-stalled replication forks and that this function is 
dependent on its GEN and not the flap endonuclease activity. 
1.5 FAN1 
1.5.1 FAN1 discovery 
The first notion of FAN1 (FANCD2-associated nuclease 1) in our lab came from a MLH1 
interactome study, where the two proteins were shown to strongly interact (155). FAN1 was 
then identified and studied in four different laboratories independently (156-160). The reasons 
for the interest in this protein were diverse; it appeared in a genome-wide shRNA screen as 
causing sensitivity to MMC (157) and MacKay et al. became interested in the protein due to 
its domain organization (159). All the studies reported the presence of a RAD18-like zinc 
finger, the UBZ domain at its N-terminus and a PD-D/E(X)K type endonuclease motif within a 
VRR-nuc (virus-type replication-repair nuclease) domain at the C-terminus. FAN1 is the only 
eukaryotic protein containing this VRR-nuc domain, which is mainly found in bacteriophages 
and bacteria as a standalone domain. It also possesses a putative DNA-binding (SAP (SAF-
A/B, Acinus, and PIAS)) domain. There are orthologs of FAN1 in prokaryotes and many 
eukaryotes, however not in budding yeast. The four initial studies all reported the sensitivity of 
FAN1-depleted human cells or C. elegans strains towards ICL agents, like cisplatin, MMC and 
HN2, but not to other DNA damaging agents that were tested (camptothecin (CPT), UV, 
ionizing radiation (IR), methyl methanesulfonate (MMS), and APH) and an increase in 
chromosomal instability after treatment with those drugs. Furthermore, it was reported that 
FAN1 colocalizes with FANCD2 at ICL-induced subnuclear foci and that FAN1 acts 
downstream of the ID2 complex, as FANCD2- or FANCI-depleted cells showed a decrease in 
the formation of FAN1 foci. Moreover, FANCD2 containing a mutation at the site of 
monoubiquitination (K561R) was not able recruit FAN1 to repair foci, indicating the 
importance of this post-translational modification in the interaction between the two proteins. 
Consistently, FAN1's UBZ domain was necessary and sufficient for focus formation and an 
immunoprecipitation (IP) experiment showed the physical interaction between FAN1 and ID2. 
Moreover, Liu et al. showed the direct interaction between FAN1 UBZ domain and ubiquitin 
and that depletion of this domain leads to hypersensitivity of the cells to MMC. The direct 
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interaction of FAN1 with the ubiquitinated ID2 complex was not shown in these studies and 
the interaction of FAN1 with another ubiquitinated partner, activated through ID2 action still 
exists. There are differences in the results to whether FAN1 is also able to interact with the 
non-modified version of FANCD2.  
In all four studies biochemical characterization of FAN1 was performed, which showed that it 
is a 5' flap endonuclease and a 5’->3’ exonuclease. It has minor endonuclease activity on 3-
way junctions and needs a gapped, nicked or recessed end as a starting point for its 
exonuclease activity, although it can also start at blunt ends with lower activity. It also 
consistently cleaves off the 5' label from the flap about 3-4 nts within the ssDNA. 
Moreover, MacKay et al. and Kratz et al. showed that the formation of foci of DSB markers is 
normal in FAN1-depleted cells treated with MMC, but that the disappearance of those foci, in 
particular of RAD51, RPA and γH2AX, is slower. This would hint towards a function for FAN1 
downstream of DSB formation, which was supported by the fact that depletion of FAN1 
reduced the efficiency of I-SceI-dependent HR. However, sister chromatid exchange was not 
elevated upon FAN1 depletion (159).  
1.5.2 Roles of FAN1 outside of ICL repair 
As FAN1 was identified by means of its interaction with MMR proteins in our laboratory, the 
possibility of an importance for this interaction and therefore FAN1 involvement in MMR 
exists. MMR involves the degradation of the error-containing strand starting from a nick, an 
action that is mainly attributed to EXO1 (exonuclease 1). Indeed, there is evidence from our 
lab and others that FAN1 can replace EXO1 in the process of MMR in vitro and in vivo (161).  
Lai et al. showed that FAN1 is degraded during mitotic exit, potentially by the anaphase 
promoting cyclosome complex (APC/C) via its activator Cdh1 (162). FAN1 might itself play a 
role in mitotic exit as this was delayed when overexpressing FAN1 in U2OS cells. Depletion 
by siRNA on the other hand, led to a faster progression through the cell cycle.  
The first notion of FAN1 potentially having a role at stalled replication forks came from 
Shereda et al., who showed that FAN1 localizes to HU-induced foci to a similar degree as 
with MMC (163). Foci formation caused by both drugs was dependent on the UBZ domain 
and on FANCD2 monoubiquitination. In another more recent study, the authors show that 
FAN1 is involved in the recovery of stalled replication forks after APH treatment together with 
BLM and FANCD2 (164). This process was independent of FANCD2 monoubiquitination or 
FAN1 UBZ domain. The authors also observed a function of the complex in the suppression 
of new origin firing. Furthermore, they proposed another, FANCD2-dependent protective 
function in stalled fork stability by restricting inappropriate degradation by FAN1.  
1.5.3 FAN1 in Schizosaccharomyces pombe 
As mentioned before, yeast does not have the FA pathway for the repair of ICLs. 
Interestingly, FAN1 only has an ortholog in Schizosaccharomyces pombe (S. pombe) and not 
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in Saccharomyces cerevisiae (S. cerevisiae). This implies, as suggested by several previous 
studies, that FAN1 has a FA-independent role in ICL repair, which can be studied in yeast. 
Fontebasso et al. did genetic analyses to dissect the different pathways to resolve ICLs in S. 
pombe (165). First, they wanted to look for a potential interaction between MMR proteins and 
Fan1 in S. pombe, but they could not find any direct physical interactions and also the 
mutation rate was not increased in fan1 deletion strains, arguing against a role of SpFan1 in 
MMR. Furthermore, fan1 deletion led to sensitivity exclusively to ICL-inducing agents, which 
was markedly increased by co-deletion of pso2, suggesting that the two gene products act in 
parallel pathways during ICL repair in S. pombe. Rhp18, the fission yeast homolog of Rad18, 
and Fml1, the homolog of FANCM were epistatic to Fan1, while Rad13, the homolog of XPG 
was epistatic to Pso2. Rad16, the homolog of XPF on the other hand was epistatic to both, 
the Fan1- and Pso2- dependent pathways. HR was also needed in both pathways. This 
suggests that in fission yeast, there are two pathways to repair ICLs. One could involve the 
recognition of the damage by Fml1, followed by Rad16- and Fan1-dependent ICL processing 
and the subsequent re-fill of the DNA by TLS pols. A second pathway could rely on Rad16, 
Pso2 and Rad13 for lesion unhooking and both pathways would result in the induction of 
DSBs, which are repaired by HR. It has to be seen whether higher eukaryotes use similar 
pathways for the repair of ICLs. 
1.5.4 FAN1 structure 
Recently, there has been an unexpected and striking accumulation of publications regarding 
FAN1, specifically concerning its structure together with some biochemical characterization 
on cross-linked substrates (166-169). All structures were obtained with FAN1 variants lacking 
the UBZ domain. The common sense is that, as opposed to the prokaryotic stand-alone VRR-
Nuc domain proteins, FAN1 does not support dimerization due to a helical insertion between 
two β sheets of the domain. Only one of the studies described dimerization of FAN1, which 
could also be an artifact of crystallization (169). The monomeric vs. dimeric forms helps to 
explain why the prokaryotic VRR-Nuc enzymes support HJ cleavage, whereas FAN1 prefers 
5' flaps. Furthermore, FAN1 has four domains - an N-terminal domain (NTD), SAP, TPR 
(tetratricopeptide repeat) and VRR-Nuc domains. Each domain plays a specific role in pre-
nick duplex, post-nick duplex, and 5' flap ssDNA recognition and in bending the DNA at the 
nick (see Figure 11). The 5' flap ssDNA is accomodated in a pocket at the interface of the 
NTD, TPR and VRR-Nuc domains. Next to the pocket, there is a hole between the TPR and 
VRR-Nuc domains, which would be big enough to accomodate ssDNA and not dsDNA. As 
FEN1 and EXO1 contain a hole where the 5' flap can enter, the same could be expected for 
FAN1. However, the flap does not pass through this hole in FAN1 but rather makes a turn in 
the opposite direction, which is wide open (166).  
Gwon et al. showed that the two-metal active site is positioned 5 nt downstream from the 
pocket that accommodates the 5' flap, explaining the flap cleavage site by FAN1 being a few 
nts within the post-nick duplex (166). The cleavage site was dependent on the position of the 
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junction between the pre-nick duplex and the ssDNA and not on the flap or any extension of 
the 3' nicked strand.  
 
Figure 11: FAN1 structure. The different domains of FAN1 are colored according to the 
graphical representation below. A line drawing of the DNA molecule is shown on the right with 
the same color code as in the cartoon of the structure. Figure adapted from (168). 
Wang et al. performed nuclease assays under physiological salt conditions and showed that 
the addition of a 3' flap increased the FAN1 binding affinity and this was explained by close 
contacts between the first two nts from the 3' flap with the protein seen in the crystal structure 
(168). Under their conditions there was a much decreased affinity and nuclease activity of 
FAN1 when incubated with 5' flaps longer than two nts compared to the shorter ones. They 
could further show that the 'exonuclease' activity is achieved by sequential (endonucleolytic) 
cuts resulting in 3 nt products. However, the sequential incisions stalled after four cuts, 
suggesting that a gap length beyond 12 nt is no longer compatible with FAN1 binding. They 
suggest that, in case of a complementary 3' flap or a polymerase in the cell, this could close 
the emergent gap and restore FAN1 binding and processivity.  
Two of the studies showed that a stable ICL (one consisting of two cytosines linked through a 
triazole moiety at their N4 positions and the other being a psoralen ICL) could be bypassed by 
FAN1, when the cross-link was located 6 nt away from the nick within the post-nick duplex. It 
cleaved both immediately 5' to the ICL and immediately 3' to it, and cleavage was less 
efficient when the cross-link was moved further away from the junction. This suggests that 
FAN1's active site is relatively flexible and can deal with possible distortions caused by the 
ICL in the DNA (168,169). 
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1.5.5 FAN1 in diseases 
As FAN1 depletion leads to hypersensitivity to cross-linking agents and it interacts with 
FANCD2, it was tempting to speculate that also FAN1 is encoded by a FA gene. Several 
groups addressed this question, e.g. Trujillo et al., who analyzed 4 patients with homozygous 
deletions of a region on chromosome 15, where FAN1 is located (170). The cells derived from 
the patients (where the lack of FAN1 expression was confirmed), scored negative for the 
classical tests for FA and also the symptoms of the patients were different from FA, which 
included microsomy, microcephaly and neurodevelopmental abnormalities, but no anemia, 
bone marrow failure or skeletal abnormalities were reported. These data, together with the 
notion that FAN1 was not epistatic to the FA pathway in chicken cells (156), exclude FAN1 as 
being a FA gene and suggests that the protein processes only a specific subset of ICLs, 
which are not addressed by the classical FA pathway. This would imply the existence of other 
nuclease(s) having redundant roles with FAN1.  
Zhou et al. instead reported that mutations in FAN1 are the cause of KIN (karyomegalic 
interstitial nephritis) in several affected families (171). 9 out of 10 families with KIN analyzed 
by sequencing had mutations in both alleles of FAN1. Also here, they report the negative 
score of the patient-derived cell lines in the typical FA test and the mutant that is defective in 
the interaction with FANCD2 (C44A/C47A) fully rescued the MMC sensitivity in the FAN1 
deficient cells, in contrast to the nuclease-dead mutant (D975A/K977A). They also depleted 
FANCD2, SLX4, XPF or MUS81 from FAN1 mutated fibroblasts and showed that the MMC 
sensitivity was greater than the single depletions, which suggests that FAN1 acts outside the 
FA pathway in a redundant fashion. Protein levels of FAN1 are particularly high in the kidney, 
which might explain the differential phenotypes by the dependencies of different organs on 
FAN1 or the FA pathway to repair ICL damage.  
FAN1 variants were further associated with schizophrenia and autism (172) as well as with 
MMR-proficient hereditary nonpolyposis colorectal cancer (173). Smith et al. just recently 
suggested FAN1 as a candidate susceptibility gene for high-risk pancreatic cancer through an 
exome sequencing study performed on these cancers (174). 
1.6 My aim 
Depletion of FAN1 renders cells sensitive towards ICL agents. Given its endo- and 
exonuclease activites, a possible function for FAN1 lies in the unhooking step, where 
endonucleases incise the DNA 5' and 3' of the ICL on the same strand. We envisioned that 
FAN1 could itself make both cleavages at either side of the cross-link, by first using its endo- 
and then its exonuclease activity to bypass the lesion. To test this hypothesis, I used synthetic 
ICL-containing DNA substrates that were generated in the laboratory of Prof. Orlando D. 
Schärer. The ICL resembles a NM-derived ICL, although its structure is less DNA distorting. 
By incubating purified FAN1 with these substrates, I could test if and how FAN1 processes 
DNA molecules bearing such an ICL. Furthermore, I made use of cell biological assays to 
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study the in vivo role of FAN1 in ICL repair. Pulse-field gel electrophoresis allowed me to 
assess the amount of DSBs in the cells after treatment with cross-linking agents. This was 
used as a surrogate for ICL unhooking as the uncoupling of ICLs during S-phase leads to the 
formation of DSBs and cells proficient and deficient for FAN1 were compared. In addition, I 
analyzed the functional redundancy between FAN1 and MUS81 by survival studies. The 
results from these studies were published in 2015 in the Journal of Biological Chemistry and 
are listed in section 3.1. Moreover, I performed studies on potential redundancies between 
the two endonucleases FAN1 and FEN1 in ICL repair. FEN1 shows a much higher activity in 
extracts on model DNA 5' flap structures than FAN1 and there is evidence that FEN1 could 
have a role in ICL repair. The results to this part are listed in section 3.2. 
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Background: We studied how the endo/exonucleases EXO1, FAN1, and FEN1 process substrates resembling replication
forks blocked by interstrand cross-links (ICLs).
Results:All three enzymes cleaved off the single-stranded 5! flap, but FAN1was also able to incise the substrate behind the ICL.
Conclusion: FAN1 can unhook ICLs.
Significance: In vivo, FAN1 may not require a 3! flap nuclease to unhook ICLs.
Cisplatin and its derivatives, nitrogen mustards and mitomy-
cin C, are used widely in cancer chemotherapy. Their efficacy is
linked primarily to their ability to generate DNA interstrand
cross-links (ICLs), which effectively block the progression of
transcription and replicationmachineries. Release of this block,
referred to as unhooking, has been postulated to require endo-
nucleases that incise one strand of the duplex on either side of
the ICL. Here we investigated how the 5! flap nucleases
FANCD2-associated nuclease 1 (FAN1), exonuclease 1 (EXO1),
and flap endonuclease 1 (FEN1) process a substrate reminiscent
of a replication fork arrested at an ICL.Wenow show that EXO1
and FEN1 cleaved the substrate at the boundary between the
single-stranded 5! flap and the duplex, whereas FAN1 incised it
three to four nucleotides in the double-stranded region. This
affected the outcome of processing of a substrate containing a
nitrogenmustard-like ICL two nucleotides in the duplex region
because FAN1, unlike EXO1 and FEN1, incised the substrate
predominantly beyond the ICL and, therefore, failed to release
the 5! flap.We also show that FAN1was able to degrade a linear
ICL substrate. This ability of FAN1 to traverse ICLs in DNA
could help to elucidate its biological function, which is currently
unknown.
DNA interstrand cross-links (ICLs)2 are highly cytotoxic
because of their propensity to block both transcription and rep-
lication (1). In all organisms studied to date, ICL repair involves
protein constituents of the nucleotide excision repair pathway,
translesion polymerases, and the machinery of homologous
recombination (2). In higher eukaryotes, ICL processing also
requires proteins of the FANC complementation group and
their interactors. Correspondingly, cells lacking these proteins
are exquisitely sensitive to ICL-inducing agents. This is of sub-
stantial clinical relevance. Mutations in genes encoding FANC
polypeptides predispose to Fanconi anemia (FA), a severe
genetic disorder characterized by bonemarrow failure, congen-
ital abnormalities and cancer predisposition, and cellular sen-
sitivity to the cross-linking agents diepoxybutane ormitomycin
C (MMC) is used in FA diagnosis (3).
Of the 17 FANC proteins identified to date, eight form the
so-called core complex, which is activated at stalled replication
forks by the ATR kinase. The FANCL subunit of the activated
core complex monoubiquitylates the FANCD2/FANCI het-
erodimer that is believed to recruit to the cross-linked site in
chromatin the polypeptides required for ICL removal (4). In the
first step, these proteins have to separate the cross-linked
strands in a process referred to as “unhooking,” in which one
strand of the duplex is nucleolytically incised on either side of
the cross-link. Studies carried out during the past three decades
helped to identify several nuclease-encoding genes, the disrup-
tion of which results in sensitivity to ICL-inducing agents, and
biochemical characterization of their respective gene products
confirmed that these nucleases could indeed be involved in ICL
unhooking. The primary candidates are SLX1-SLX4, XPF-
ERCC1, MUS81-EME1, SNM1A, and FAN1. Despite some
seminal mechanistic studies that have been described in the
recent literature (reviewed in Ref. 5), our understanding of the
possible functions of these enzymes in ICL unhooking is still
rudimentary. The situation is further complicated by functional
redundancies of several of the involved proteins, their interplay
with other members of the ICL repair pathway, and differences
in helical distortions induced by different types of ICLs (6).
FANCD2-associated nuclease 1 (FAN1) has been identified
independently in four laboratories (7–10). It possesses a con-
served PDXn(D/E)XK active site motif common to the restric-
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tion nuclease-like superfamily. This site is embedded in a VRR-
nuclease domain, the structure of which has been solved
recently (11). FAN1 has been implicated in ICL repair because
its knockdown (7–10) or knockout (12, 13) caused sensitivity to
the ICL-inducing agents MMC and cisplatin. The protein con-
tains also a ubiquitin-binding zinc finger domain, which is nec-
essary and sufficient for its recruitment to MMC-induced foci
of the monoubiquitylated form of FANCD2/I (7–10). As a con-
sequence, FAN1 was predicted to be a novel FANC protein.
However, experiments with chicken DT40 knockout cell lines
failed to yield evidence of an epistasis between FAN1 and
FANCC or FANCJ (13), and no mutations in FAN1 were iden-
tified in unassigned FA patients. Instead, FAN1 loss has been
linked to karyomegalic interstitial nephritis (14). Therefore,
even though its involvement in ICL processing is beyond doubt,
FAN1 does not appear to be a FANC protein. However, current
evidence does not exclude the possibility that FAN1 does par-
ticipate in the FANC pathway but that its deficiency does not
lead to FA because of functional redundancy with other
polypeptide(s).
In an attempt to address the latter point, we set out to com-
pare how structures resembling ICL-blocked replication forks
are addressed by three 5! flap endonucleases and 5! to 3! exo-
nucleases with known roles in DNA replication and repair:
EXO1, FAN1, and FEN1. EXO1 (15) and FEN1 (16) belong to
the same enzyme family and have been reported to incise 5! flap
structures primarily one nucleotide 3! from the single-strand
(ss)/double-strand (ds) junction (for a review, see Ref. 17).
FAN1 has been shown to incise 5! flap structures two to four
nucleotides 3! from the ss/ds junction (9). Given their similar
substrate specificities, we wondered whether these enzymes
could compensate for one another in ICLprocessing.We there-
fore synthesized a 5! flap structure containing a single cross-
link resembling an ICL induced by nitrogen mustards (NMs),
positioned two nucleotides 3! from the ss/ds junction (18). As
controls, we also synthesized a linear duplex containing a sim-
ilar ICL as well as several unmodified substrates.We now show
that all three enzymes could cleave the 5! flaps but that FAN1
was also able to traverse the cross-link on both ICL substrates.
Furthermore, we show that FAN1 depletion leads to a reduc-
tion in the number of MMC-induced double-strand breaks
(DSBs). This could imply that FAN1-dependent processing of
ICLs leads to the generation of repairable DSBs, whereas FAN1
absence or malfunction may lead to ICL persistence and
cytotoxicity.
Experimental Procedures
Antibodies—Sheep !-KIAA1018/MTMR15 (a gift from J.
Rouse, 1:625), rabbit !-TFIIH (Ser-19, Santa Cruz Biotechnol-
ogy, 1:1000),mouse!-MUS81 (Sigma, 1:2000),mouse!-Lamin
B1 (Abcam, 1:100), rabbit !-"H2AX (Ser-139, Cell Signaling
Technology, 1:1000), mouse !-RPA2 (Calbiochem, 1:50),
mouse !-CtIP (Asp-4, Santa Cruz Biotechnology, 1:250), and
rabbit !-pRPA2 (Ser-4/Ser-8, Bethyl Laboratories, 1:500) were
used.
siRNATreatments—The following siRNAs (Microsynth, Bal-
gach, Switzerland) were used: siFAN1, GUAAGGCUCUUUC-
AACGUA; siLuciferase, CGUACGCGGAAUACUUCGA; and
siMUS81, CACGCGCTTCGTATTTCAGAA and CGGGAG-
CACCTGAATCCTAAT. The siRNA treatments were car-
ried out 1 day after seeding the cells at "30% confluency in
10-cm dishes. The transfection agent was Lipofectamine
RNAiMAXTM (Invitrogen), which was used according to the
instructions of the manufacturer.
Synthesis of Substrates—DNA ICLs were synthesized as
described in Refs. 19, 20. Unmodified oligonucleotides were
purchased from Microsynth. Sequences and graphical repre-
sentation of the substrates can be found in Figs. 1A, 2A, 3A,
and 4A.
Labeling and Annealing of Unmodified Substrates—The 5!
labeled flap substrate shown in Fig. 1Awas generated by anneal-
ing oligonucleotide I labeled at its 5! terminus with T4 polynu-
cleotide kinase (New England Biolabs) and ["-32P]ATP (Hart-
mann Analytic) to the unlabeled oligonucleotides II and III at
95 °C and cooling down to room temperature in annealing
buffer (25 mM Hepes-KOH (pH 7.4) and 50 mM KCl).
The 5! labeled flap substrates shown in Fig. 4A were gener-
ated by annealing either the 5!-labeled oligonucleotide VII with
the unlabeled oligonucleotides IX, XI, and XII or the 5!-labeled
oligonucleotide VIII with the unlabeled oligonucleotides X, XI,
and XII. The 3!-labeled substrates were generated by first
annealing oligonucleotides I and IV (Fig. 2A) or V and VI (Fig.
3A), and filling in the overhangs using Klenow polymerase
(New England Biolabs) and [!-32P]dTTP (Hartmann Analytic)
together with dATP, dCTP, and dGTP, followed where
required by reannealing with oligonucleotide III (Fig. 2A).
Labeling and Annealing of ICL Substrates—The 5! flap sub-
strates were generated by labeling the 5! termini of the cross-
linked Y structure (oligonucleotides I and II, Fig. 1A) with T4
polynucleotide kinase (New England Biolabs) and ["-32P]ATP
and annealing with oligonucleotide III as described above. The
3!-labeled cross-linked substrates (Figs. 2A and 3A) were gen-
erated by filling in the overhangs using Klenow polymerase
(New England Biolabs) and [!-32P]dTTP together with dATP,
dCTP, and dGTP, followed by annealing with oligonucleotide
III (Fig. 2A) as described above. The recessed substrate (5!
CCCTCTTCTXTCCTTCTTTC 3!/5!GAAAGAAGXACA-
GAAGAGGGTACCATCATAGAGTCAGTG 3!, where X
represents the cross-linked guanines, Fig. 3F) was labeled at the
ds 3! end by cordycepin (PerkinElmer Life Sciences) and termi-
nal transferase (Roche).
In Vitro Nuclease Assays—WT andmutant FAN1 were puri-
fied as described previously (9) and dialyzed against nuclease
buffer (25 mM Hepes-KOH (pH 7.4, FAN1, or pH 7.8, EXO1
and FEN1), 25mMKCl, 1mMMgCl2, 0.5%PEG, and 0.05mg/ml
BSA) for 15 min at 4 °C before use. WT and mutant recombi-
nant purified human EXO1 was a gift from Stephanie Bregen-
horn (21). FEN1 was purchased from Gentaur (catalog no.
C140). Unless stated otherwise, the nuclease assays were car-
ried out by incubating the substrates for 30 min at 37 °C in the
appropriate nuclease buffer (see above). Aliquots were with-
drawn at the indicated time points,mixedwith an equal volume
of loading dye (80% formamide, 50mMTris-HCl (pH 8.3), and 1
mM EDTA), and loaded on 20% denaturing polyacrylamide gels
(20# 20# 0.05 cm) that were run in TBE buffer for 1 h at 800
V. The gels were fixed, dried, and exposed to phospho screens,
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which were then scanned in a PhosphorImager (Typhoon 9400,
GE Healthcare). Quantification of the bands was carried out
using ImageJ, and the graphs were generated using GraphPad
Prism. The overall efficiency of substrate processing was
obtained by dividing the integral values of all the product bands
by the integral value of all the bands. The cleavage efficiencies of
the 5! flaps in the unmodified and ICL substrates were calcu-
lated by dividing the integral values of the product bands by the
integral value of all bands.
Pulsed FieldGel Electrophoresis—Pulsed field gel electropho-
resis was performed as described previously (22) with minor
modifications. 24 h after MMC treatment (3 !g/ml), cells were
harvested, and agarose plugs containing 250,000 cells/plug
were generated. Quantifications were done using ImageJ, and
graphs were produced using GraphPad Prism.
5-Ethynyl-2!-deoxyuridine (EdU) Staining and FACS
Analysis—After treating the cells with 10 !M EdU (Life Tech-
nologies) for 30 min, they were harvested, fixed in 1% formal-
dehyde, and labeled using the Click-iT! cell reaction buffer kit
(Life Technologies) according to the instructions of the manu-
facturer. DNAwas stainedwith 1!g/ml DAPI, and the samples
were analyzed on a Cyan ADP flow cytometer (Beckman
Coulter) fitted with Summit software v4.3 (Beckman Coulter).
Clonogenic Survival Assay—Survival assays were performed
as described previously (9). Eight days after treating the cells
with MMC or carmustine (bromo-chloro-nitrosourea, BCNU)
at the indicated dosages, the cells were fixed and stained with
0.5% crystal violet in 20% ethanol, and colonies containing
more than 50 cells were counted. MMC-containing medium
was replaced with fresh medium after 24 h.
Results
An NM-like ICL Does Not Block the Endonuclease Activity of
FAN1 on a 5! Flap Substrate—The ability of FAN1 to cleave
substrates containing 5! flaps, coupled to the sensitivity of
FAN1-depleted cells to ICL-inducing agents (7–10), indicates
that this protein might be involved in ICL unhooking. Experi-
mental evidence implicating FAN1 in this process has, how-
ever, not been forthcoming. In Xenopus laevis egg extracts,
FAN1 depletion caused no detectable defect in unhooking of a
single ICL in a plasmid substrate, but this could be explained by
functional redundancy with other nucleases in the extract (23).
To learn with which nuclease FAN1 could be redundant, we set
out to test its ability to process a 5! flap substrate containing a
single NM-like ICL (Fig. 1A) and compared it with those of two
other 5! flap endonucleases, EXO1 and FEN1. FAN1-catalyzed
cleavage of the control, unmodified 5! flap substrate labeled at
the 5! terminus of the flap gave rise to several species between
11 and 21 nucleotides in length, the most prominent of which
was a 19-mer arising as a product of endonucleolytic cleavage of
the lagging (flap-containing) strand four nucleotides 3! from
the ss/ds junction (Fig. 1B, lanes 1–6, products a).
EXO1 and FEN1 belong to the same nuclease family, possess
highly conserved active sites, and have been reported to cleave
5! flaps preferentially one nucleotide 3! from the ss/ds junction
(17). They were therefore both expected to release 16-mer flaps
from the unmodified substrate (Fig. 1A). Somewhat surpris-
ingly, the flap fragments generated by the two enzymes differed.
The main product of EXO1-catalyzed cleavage was a 17-mer,
whereas FEN1 generated predominantly a mixture of 15-mer
and 16-mer fragments (cf. Fig. 1, C and D, lanes 1–6). Both
enzymes are known to bind to the template strand and bend the
DNA at the break. Our result suggests that the 90° bend intro-
duced by EXO1 binding (17) partially melted the flap-contain-
ing strand to generate a single nucleotide gap between the 3!
terminus of the leading strand primer and the ss/ds boundary
and subsequently cleaved the substrate 3! from the first nucle-
otide of the duplex. The FEN1-generated products can also be
explained by itsmodus operandi. It bends the substrateDNAby
100°, melts two base pairs downstream of the ss/ds boundary,
and cleaves the strand between these two extruded nucleotides.
This would explain the origin of the 16-mer fragment. The ori-
gin of the 15-mer can also be explained. FEN1 prefers to gener-
ate directly ligatable products and achieves this by binding and
bending theDNAso that the 3! end of the leading strand primer
melts to give rise to a single-nucleotide 3! flap. The ss/ds
boundary in this structure is shifted by one nucleotide in the 5!
direction. Cleavage of this 5! flap between the two extruded
nucleotides would then liberate a 15-mer flap and leave behind
a nick that can be ligated.
Analysis of products generated by the three nucleases from
the 5! phosphorylated cross-linked substrate was slightly com-
plicated by the fact that the oligonucleotide had to be labeled by
polynucleotide kinase after ICL synthesis, which means that
both 5! termini were labeled even though the ds end was phos-
phorylated less efficiently than the ss flap. This increased the
number of possible products shown in Fig. 1A, right panel.
FEN1 flap endonuclease activity was only weakly inhibited by
the presence of the ICL (Fig. 1D, bottom panel). Because this
enzyme lacks exonuclease activity on blunt-ended, double-
stranded DNA, product b’ was clearly detectable, as were the
released flap products (a’), of which the 15-mer predominated
(Fig. 1D, lanes 7–12). EXO1 activity on the ICL substrate was
inhibited (Fig. 1C, bottom panel), as judged by the lower inten-
sity of bands a’ compared with bands a. Interestingly, EXO1
failed to release the 17-mer flap from the ICL substrate (Fig. 1C,
lanes 7–12).
As shown in Fig. 1B, lanes 7–12, the abundance of flap frag-
ments a/a’ arising through cleavages 5! from the ICL by
FAN1 was almost comparable with the unmodified and
cross-linked substrates, as shown by the intensity of the
15–17-mer bands (red arrowheads) relative to the full-length
substrate (Fig. 1B, bottom panel). Because of the fact that the
lower substrate strand was also labeled, products d’ (Fig. 1A)
were also detectable in the autoradiograph (Fig. 1B, lanes
7–12). Products c’ were generated by a 5!-to-3! degradation
from the blunt-ended 5! terminus of the ICL substrate, but
the nature of band d’ was uncertain. However, given that it
migrated only slightly slower than the 37-mer, we postulated
that it might correspond to species d’, shown in Fig. 1A (see
also below).
The most notable difference between the FAN1-generated
products of the unmodified and the ICL substrate, however,
was the absence of the 19-mer product in the latter reactions
(Fig. 1B, cf. lanes 1–6 and 7–12). On the basis of the cleavage
pattern of the unmodified flap substrate, this incision would
FAN1-catalyzed Unhooking of ICLs
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have occurred on the 3! side of the cross-link, and, therefore,
the labeled flap fragment would not have been released from
the substrate. In the experiments described above, we used
recombinant FAN1 and EXO1 expressed in Sf9 cells and bac-
teria, respectively. To ensure that the observed enzymatic activ-
ities were indeed due to these polypeptides rather than contam-
inating nucleases, we also generated nuclease-dead variants of
FAN1 (D960A) and EXO1 (D173N). As shown in Fig. 1E, the
inactive variants generated no products comparable with those
generated by the wild-type proteins.
To verify the incision on the 3! side of the cross-link experi-
mentally, we labeled the substrates at the 3! termini of the
upper strand (Fig. 2A). As anticipated, FAN1 (7–10), EXO1
(16), and FEN1 (24) degraded the unmodified substrate exonu-
cleolytically from the sites of their respective endonucleolytic
incisions in a 5!-to-3! direction, with EXO1 (Fig. 2C, lanes 1–6)
beingmore efficient than FAN1 (Fig. 2B, lanes 1–6), whichwas,
in turn, more efficient than FEN1 (Fig. 2D, lanes 1–6). Most of
the products detected in the FAN1-catalyzed degradation were
longer than 11 nucleotides, which suggested that this enzyme
might require a dsDNA stretch of "10 base pairs to which to
bind. In contrast, EXO1 appeared to completely degrade the
incised strand. FEN1 predominantly generated product a from
the unmodified substrate. Incubation of the ICL substrate with
EXO1 generated species c’ as the primary product, and lower
amounts of species a’ and d’ (Fig. 2C, lanes 7–12), which sug-
gests that this enzyme may prefer a blunt-end terminus to a 5!
flap as a substrate (15). FEN1 predominantly yielded product a’
FIGURE1.Comparisonof5! flapendonucleaseactivitiesandthespecificitiesofFAN1,EXO1,andFEN1.A, schematic representationof theDNAsubstrates
used in this study. The unmodified flap substrates (left panel) were generated as described under “Experimental Procedures,” and the labeling of the flap
substrates with a nitrogenmustard-like interstrand cross-link (right panel, cross-link shown in red) resulted primarily, but not exclusively, in the labeling of the
I strand. The likely products generated by the above enzymes from these substrates are also shown. Red asterisks indicate the positions of the 32P-labeled 5!
phosphates. Fragments invisible on the autoradiograph are shown in gray.Dashed lines represent regions of exonucleolytic degradation. nt, nucleotides. B–D,
product generated upon incubation of the substrates shown above the panelswith FAN1 (B), EXO1 (C), and FEN1 (D). Aliquotswerewithdrawn at 0, 10 s, 2min,
20min, 40min, and 80min (B, lanes 1–6 and 7–12, respectively) or at 0, 10 s, 1 min, 10min, 20min, and 40min (C andD, lanes 1–6 and 7–12, respectively). The
protein-to-DNA ratios were 1:1 for FAN1 and EXO1 and 1:2 for FEN1.M, lowmolecular weight marker (Affymetrix). The oligonucleotide sizes are indicated on
the left, and the position of the cross-link is indicated by a black arrowhead. The lowercase letters on the right correspond to the products in A. (Products b’–d’
are seen solely in the reactions using the cross-linked substrate, in which both strandswere labeled.) The black asterisk indicates the position of the non-cross-
linked 35-mer oligonucleotide that was present in small amounts in the ICL substrate. The graphs below the autoradiographs of 20% denaturing polyacryl-
amidegels represent thequantificationof either all productbands (total) or of only thebands indicated in red (arrowheads). Themostprominentproductbands
in the reaction of FAN1with the unmodified substrate resulted from incisions beyond the position of the ICL and are therefore not detectable in digestions of
the cross-linked substrate. Error bars showmean# S.D. (n$ 3). E, comparative analysis of digestions of the indicated 5! flap substrates by the three structure-
specific endonucleases, including the nuclease-dead mutants of FAN1 (D960A) and EXO1 (D173N). DNA and proteins were all in equimolar ratios, and the
reactions were carried out for 30 min at 37 °C.
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(Fig. 2D, lanes 7–12). This indicated that both enzymes made
their primary endonucleolytic incisions 5! from the ICL at posi-
tion 18 of the labeled strand and that their exonuclease activity
failed to traverse the cross-link. In contrast, incubation of the
unmodified and the ICL substrate with FAN1 yielded similar
products (Fig. 2B, cf. products b and b’, lanes 1–6 and lanes
7–12), which arose from incisions in the labeled strand on the 3!
side of nucleotide 18 (and, therefore, 3! from the cross-link in
the ICL substrate) and their subsequent 5! to 3! degradation.
Fig. 2E shows again that the activities were due to the enzymatic
activities of FAN1 and EXO1 because their mutants failed to
generate the specific products.
FAN1 Can Degrade a Linear Duplex Containing an ICL—
Our experiments carried out with the 5!-labeled substrates
showed that the flap endonuclease of FAN1 was relatively pro-
miscuous because it incised the structures both 5! and 3! of the
ss/ds boundary. Moreover, its activity did not appear to be
influenced by the presence of the cross-link. Given that the
enzyme is also a robust 5! to 3! exonuclease, as seen with the
3!-labeled substrates, wewanted to testwhether the presence of
a cross-link affected the latter activity. We therefore generated
linear duplex substrates, either unmodified or containing a sin-
gle ICL (Fig. 3A). As shown in Fig. 3, B—D, lanes 1–6, all three
enzymes were able to degrade the unmodified 3!-labeled sub-
strate, albeit inefficiently. Unexpectedly, FAN1 digestion gave
rise to a similar range of short oligonucleotide products as those
seen with the unmodified substrate (Fig. 3B, cf. lanes 1–6 and
7–12), which indicated that the enzyme traversed the ICL. This
result confirms the nature of product d’ in Fig. 1B. In contrast,
EXO1 and FEN1 generated a series of products b’ from the ICL
substrate (Fig. 3,C andD, lanes 7–12), which indicated that the
enzyme was arrested by the ICL. As shown in Fig. 3E, the inac-
tive variants generated no products comparablewith those gen-
erated by the wild-type proteins.
We then tested FAN1 (WT and D960A) activity on a linear
ICL substrate with a recessed 5! terminus. Also on this sub-
FIGURE 2. Comparison of 5! to 3! exonuclease activities and the specificities of FAN1, EXO1, and FEN1. A, schematic of the DNA substrates used in
this study. The unmodified flap substrates (left panel) and the substrates with a nitrogenmustard-like interstrand cross-link (right panel, cross-link shown
in red) were produced as described under “Experimental Procedures.” Schematics of products generated by the above enzymes are shown next to the
corresponding substrates. Red asterisks indicate the positions of the 32P-labeled nucleotides. Fragments invisible on the autoradiograph are shown in
gray. B–D, incubation of the indicated substrates with FAN1 (B), EXO1 (C), or FEN1 (D). Aliquots were withdrawn after 0, 10 s, 2 min, 20 min, 40 min, and
80min (B, lanes 1–6 and 7–12, respectively) or 0, 10 s, 1 min, 20 min, and 40min (C and D, lanes 1–6 and 7–12, respectively). Lowercase letters on the right
correspond to the products in A. The protein-to-DNA ratios were FAN1 (10:1), EXO1 (3.5:1), and FEN1 (1:2).M, lowmolecular weight marker (Affymetrix).
The oligonucleotide sizes are indicated on the left. The black asterisk indicates the position of the non-cross-linked 37-mer oligonucleotide that was
present in small amounts in the ICL substrate. The graphs below the autoradiographs of 20% denaturing polyacrylamide gels show the quantification
of bands a or b, respectively. b’ was generated by incisions in the top strand. Error bars show mean" S.D. (n# 3). E, comparative analysis of cleavage
products generated on the 3! side of the cross-link by the three nucleases as well as by the nuclease-dead mutants of FAN1 (D960A) and EXO1 (D173N).
The reaction conditions were as in Fig. 1E.
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strate, theWTFAN1 protein was able to traverse the cross-link
(Fig. 3F, lanes 1–5 (WT) and 6–8 (D960A)).
FAN1Requires Regions of!10 Base Pairs on Either Side of the
Flap for Cleavage—The experiments described above provided
us with novel information concerning the biochemical proper-
ties of FAN1. Could these data help elucidate the role of FAN1
in ICLprocessing in vivo? That FAN1 is involved in ICLdamage
processing is beyond doubt, given that cells lacking the full
complement of this protein are hypersensitive to cisplatin,
MMC (7–10), and the nitrogen mustard BCNU (Fig. 5E). It is,
however, unclear, which structures it addresses in genomic
DNA and which products it generates. Evidence obtained from
experiments carried out with an ICL-containing plasmid sub-
strate andX. laevis egg extracts indicated that a replication fork
encountering a cross-link stalls initially 20–40 base pairs from
it because of the CDC45/MCM2–7/GINS replicative helicase
remaining on the leading strand. This intermediate is not
incised in this experimental system but persists until the arrival
of the second fork from the opposite direction. Both helicase
complexes are then unloaded, and the forks converge on the
ICL. Unhooking was detected when the forks were just a single
base pair from the cross-link (Ref. 25 and references therein). In
this system, the nucleases primarily responsible for unhooking
are believed to be SLX1/SLX4 on the 5" side of the ICL and
XPF/ERCC1on the 3" side (23). FAN1has been shownnot to be
necessary (5, 23), and this finding is supported by our data,
which suggest that FAN1 would not incise the X structure gen-
erated by the convergence of the two forks because it appears to
require the ICL to be flanked by dsDNA on both sides of the
flap, as witnessed by the fact that a Y junction is a poor FAN1
substrate (9) and that its exonuclease activity failed to generate
fragments shorter than!10 nucleotides (Fig. 2B). This suggests
that FAN1 requires at least this length of dsDNA for binding.
We decided to test this hypothesis directly by generating two
X-like substrates reminiscent of two converging replication
forks separated by 12 (X-12) or eight (X-8) nucleotides (Fig.
4A). As shown in Fig. 4B, the former substrate was processed
more efficiently than the latter by FAN1 WT but not by the
D960A mutant. This difference was not caused by the lower
stability of the X-8 substrate. Both the X-12 and X-8 substrates
were annealed efficiently under the assay conditions, as shown
by native PAGE (Fig. 4B, bottom right panel). Therefore, cou-
pled with the finding that the enzyme processes Y structures
with only limited efficiency (9), the above result confirms our
hypothesis that FAN1 requires regions of !10 base pairs on
either side of the 5" flap for cleavage.
FIGURE 3. FAN1 can also traverse a cross-link on a linear DNA substrate. A, schematic of the linear DNA substrates labeled at the 3" terminus of the upper
strand by fill-in reactions with [!-32P]dTTP. A schematic of the expected products is shown next to the corresponding substrates (a, b, and a’–c’). Red asterisks
indicate the positions of the 32P-labeled nucleotides. Fragments invisible on the autoradiograph are shown in gray. B–D, 5" to 3" exonuclease activities of FAN1
(B), EXO1 (C), and FEN1 (D) on the indicated substrates. Reaction conditions and protein concentrations were as in Fig. 2. Lowercase letters correspond to the
products in A.M, lowmolecular weight marker (Affymetrix). The oligonucleotide sizes are indicated. The black asterisk indicates the position of the non-cross-
linked 28-mer oligonucleotide that was present in small amounts in the ICL substrate. Bottom panels, quantifications of the degradation fragments. Error bars
show mean # S.D. (n $ 3). E, comparative analysis of cleavage products generated on the 3" side of the cross-link by the three nucleases as well as by the
nuclease-deadmutants of FAN1 (D960A) andEXO1 (D173N). The reaction conditionswere as in Fig. 1E. F, FAN1WTandD960Aactivity on a recessed linearDNA
substrate shownschematically above. Concentrationswereas indicated, and sampleswerewithdrawnafter 1, 10, 30, or 60min (WT, lanes 2–5) or after 1, 30, and
60 min (D960A, lanes 6–8). For the substrate sequence, see “Experimental Procedures.” Quantifications are as indicated above. Black asterisks indicate the
non-cross-linked oligonucleotides present in the substrate preparation. The dashed line represents missing lanes.
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MMC-induced DSBs Are Partially FAN1-dependent—If
FAN1 is not involved in the resolution of replication forks con-
verged at an ICL, then which structures does it address in vivo?
This question is extremely difficult to answer, but it might be
possible to gain some insights from the analysis of the products
it generates fromDNA treatedwith ICL-inducing agents. Proc-
essing of ICL-arrested replication forks by the FANC pathway
(5) leads to lesion unhooking and to the generation of one or
two DSBs that are subsequently repaired by homologous
recombination (2). Some years ago, the MUS81 gene was also
implicated in ICL repair. Like FAN1, MUS81 is not a known
FANC gene. It encodes a protein that associates with EME1 to
formaheterodimer that possesses 3! flap endonuclease activity.
Disruption of theMus81 locus in the mouse resulted in sensi-
tivity to ICL-inducing agents and to a decreased number of
MMC-induced DSBs in ES cells in S phase, as shown by pulsed
field gel electrophoresis (26). This suggested that Mus81 might
be involved in the conversion of ICLs toDSBs, which are in turn
repaired by recombination (22).We decided tomake use of this
assay to learn whether we could find evidence of similar pro-
cessing of ICL-containing DNA by FAN1. We treated U2OS
(osteosarcoma) cells with siRNAs targeting either luciferase
(negative control), FAN1, and/or MUS81 and, 2 days later,
exposed them to MMC. Western blot analysis of extracts iso-
lated 24 h after MMC treatment revealed that FAN1 and/or
MUS81 knockdown was associated with a reduction in phos-
phorylation of replication protein A (RPA), CtIP, and H2AX
(Fig. 5A), indicative of less extensive resection of DSBs. This
was confirmed by an analysis of genomic DNA 18, 24, and 30 h
afterMMC treatment. As shown in Fig. 5B, the number ofDSBs
was reduced in FAN1 or MUS81 knockdown cells compared
with the control. Surprisingly, quantification of the 24-h time
point (Fig. 5C) revealed that knockdown of both MUS81 and
FAN1gave rise to a similar number ofDSBs as the FAN1knock-
down alone. This effect was not caused by a proliferative defect
of the siRNA-treated cells, as confirmed by EdU incorporation
and FACS analysis (Fig. 5D). The finding that knockdown of
FAN1 or MUS81 resulted in a similar sensitivity to MMC or
carmustine and that knockdown of bothmRNAs failed to cause
additional sensitization (Fig. 5E) suggested that the two pro-
teins might act together in the processing of a subset of ICL
substrates.
Discussion
The current hypotheses of ICL processing (5) posits that the
repair machinery has to deal with either one of two distinct
replication-dependent lesions: a single fork arrested at the ICL
(Fig. 6A) or an X-shaped structure that arises at the cross-link
through the convergence of two forks or through replication
fork traverse through the ICL (Fig. 6B). Our findings suggest
that FAN1 would be able to process the single arrested fork
alone by first releasing the flap and then unhooking/traversing
the ICL to leave behind a short oligonucleotide attached to the
leading strand template that could be bypassed by translesion
polymerases (Fig. 6C). However, this scenario would apply
solely if FAN1 were able to incise the flap when the ICL was
more than four nucleotides 3! from the ss/ds boundary. If it
were closer, FAN1 would fail to release the flap. FAN1 could
also initiate the processing of an X-shaped structure, by releas-
ing the lagging strand flap and, therefore, forming a substrate
for a second nuclease, such as MUS81, which could release the
3! flap formed by the leading strand of the second fork. This
mechanism would only work if the two forks were at least 15
base pairs apart, with the ICL being positioned more than four
nucleotides from the left ss/ds boundary (Fig. 6D) to provide
FIGURE 4.FAN1 cleavage requires"10basepairs of dsDNAonboth sides
of the flap. A, schematic of the X-12 and X-8 substrates. The tetranucleotide
sequence in parentheses is absent from the X-8 substrate. The asterisk indi-
cates the 32P-labeled phosphate. B, the substrates were incubated with the
enzymes at the indicated enzyme:substrate ratio at 37 °C for 1, 10, 30, and 60
min (FAN1-WT, lanes 1–5 and 10–14; FAN1 D960A, lanes 6–9) or 1 and 60min
(lanes 15 and 16). The X-8 substrate was extremely inefficiently processed
even at 30 °C (bottom left panel), which indicates that the lack of flap cleavage
was not caused by denaturation (denat) of the X structure. (Only the bands
indicated by the arrowheadswere quantified.) Bottom right panel, 10% native
polyacrylamide gel of the two substrates, incubated at 37 °C for 30 min. This
additional control experiment shows that both substrates were predomi-
nantly annealed under the conditions of the reaction.
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FIGURE 5. FAN1- and/or MUS81-dependent DSB induction upon MMC treatment of human cells. A, top panel, FAN1 and/or MUS81 siRNA-mediated
knockdown efficiencies assessed byWestern blotting of total cell extracts of untreated (!) orMMC-treated (") U2OS cells. TFIIHwas used as a loading control.
Quantification of the knockdown efficiencies shown in the bottom panelwas carried out using ImageJ, and the graph was produced by GraphPad Prism (n#
3). The same extracts were probed for themarkers of DSBmetabolism RPA and CtIP. Center panel, Western blot analysis of the chromatin-enriched fraction of
the above extracts probed for RPA, phospho-RPA, and !H2AX. Laminwas used as the loading control. B, time course of DSB formation assessed by pulsed field
gel electrophoresis after MMC treatment (3 "g/ml) of U2OS cells, in which FAN1 or MUS81 were knocked down by siRNA. C, representative pulsed field gel
electrophoresis imageofDSBs inducedby 24hMMC (3"g/ml) treatment of U2OS cells inwhich FAN1 and/orMUS81were knockeddown. The left panel shows
a quantification of three independent experiments. siLUC was used as a control, and the ratio of DSBs of the MMC-treated samples divided by the untreated
samples is shown for each siRNA condition. Error bars showmean$ S.E.D, quantifications of a FACS analysis of EdU-labeled cells pretreatedwith the indicated
siRNAs and subsequently treated for 24 h with 3"g/ml MMC. The knockdown did not affect cell viability during the course of the experiment. Error bars show
mean$ S.E. (n# 3). E, clonogenic survival assay of U2OS cells treatedwith the indicated siRNAs and drugs. Colonies were counted 8 days after treatment, and
MMC was washed out 24 h after treatment.
FIGURE 6.Theputativemechanismof FAN1-dependent ICLunhooking.A, schematic of a single replication fork arrested at an ICL. B, the X-shaped structure
arising through the convergence of two replication forks at an ICL. C, a single fork arrested at an ICL that is more than 5 bp from the ss/ds boundary would be
incised by FAN1 5% from the ICL, whichwould release the lagging strand. The enzymewould then degrade the nicked strand in a 5%-to-3% direction to generate
a substrate for translesion polymerases and subsequent repair by nucleotide excision repair.D, an X-shaped structure that contains a duplex longer than 10bp
where the lagging and leading strand flaps could be released by the action of FAN1 and, e.g., MUS81.
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FAN1 with a duplex platform to which it has to bind on either
side of the flap (see above).
The hypothesis of ICL processing favoring the convergence
of two forks arriving from opposite directions has recently
received additional support (25). Of the known 5! flap endonu-
cleases, SLX1/SLX4 is emerging as the strongest candidate for
introducing the first incision,withXPF/ERCC1being the prime
candidate for the 3! incision. The involvement of FAN1 in the
processing of a subset of these structures, where the forks
remained some distance apart because of topological restraints,
for example, cannot be excluded. But FAN1 does not necessar-
ily have to be involved in ICL processing. We originally pro-
posed that the enzyme might be involved downstream of the
unhooking step, possibly during homologous recombination,
because the enzymeprocessed aD loop structurewith very high
efficiency and because foci of !-H2AX, RPA, and RAD51,
which are generally believed to be markers of DSBs, appeared
with similar kinetics in FAN1-proficient and knockdown cells
but persisted longer in depleted cells (9), and depletion of
MUS81 results in a similar phenotype (27). Interestingly, these
foci also form after replication fork stalling (22, 28–30), and
FAN1 has been reported to accumulate at replication forks
stalled by aphidicolin (31). It is therefore possible that the per-
sistent foci of !-H2AX, RPA, and RAD51 represent stalled rep-
lication forks that collapsed because of the deficiency in
enzymes able to mediate their restart and that are being pro-
cessed by an alternative, less efficient mechanism.
Recently, the crystal structure of Pseudomonas aeruginosa
FAN1 bound to a 5! flap (32) revealed that the enzyme (lacking
the ubiquitin-binding zinc finger domain) bends the DNA at
the flap position by extensively interacting with the dsDNA
regions on either side of the flap and that it cleaves the fourth
phosphodiester moiety 3! from the ss/dsDNA boundary. These
observations fully agree with our findings. When our manu-
script was in the final stages of preparation, two additional pub-
lications described the crystal structure of human FAN1 (also
lacking the ubiquitin-binding zinc finger domain) bound to dif-
ferent flap substrates. In one study (33), FAN1 was shown to
bind with a much greater affinity to substrates containing a
5!-phosphorylated flap of only one or two nucleotides, which it
then incised in exonucleolytic steps of three nucleotides. In this
way, it was able to unhook a triazole cross-link in a way analo-
gous to that described in our study. The second study deployed
a series of substrates in which the position of the ICL was
moved further away from the ss/ds boundary of the flap (34). In
the latter work, cleavage efficiency was seen to increase as the
cross-link wasmoved 6, 12, or 16 base pairs away from the ss/ds
boundary. Thiswork predicted that, on the latter substrates, the
enzyme would successfully traverse the ICL. In this scenario, it
would be able to unhook the cross-linkwithout the assistance of
other enzymes. Taken together, our study and those ofWang et
al. (33) and Zhao et al. (34) demonstrate that FAN1 can cleave
long 5! flaps such as those that would arise at blocked replica-
tion forks but that the enzyme may also process and unhook
short flaps and nicks generated at ICLs by other nucleases that
may not be able to bypass the ICL. In the latter reaction, FAN1
may be partially redundant with SNM1A, as is the case in
Schizosaccharomyces pombe (35). Like FAN1, the latter enzyme
has the ability to traverse cross-links, providing that a single-
stranded nick 5! from the ICL is present in the vicinity (36).
Because ICLs block the progression of transcription and rep-
licationmachineries and because they can bring about different
distortions in the helical structure ofDNA (37), it is not surpris-
ing that nature has evolved several mechanisms of dealing with
these extremely cytotoxic lesions. The investigation of which
enzyme or pathway acts when and on which substrate(s) must
await the outcome of genetic experiments that are currently in
progress in several laboratories.
Author Contributions—J. P. helped design and carried out the exper-
iments and cowrote themanuscript. S. M. synthesized the ICL oligo-
nucleotides; O. D. S. helped design the experiments; and J. J. con-
ceived the study, helped design the experiments, and wrote the
manuscript.
Acknowledgments—We thank Anja Saxer for technical help. We also
thank Stephanie Bregenhorn for the purified recombinant EXO1,
Pavel Janscak for the MUS81 antibody, Alessandro Sartori for the
CtIP antibody, and Svenja Kaden for helpful discussions and critical
reading of the manuscript.
References
1. Schärer, O. D. (2005) DNA interstrand crosslinks: natural and drug-in-
duced DNA adducts that induce unique cellular responses. Chem-
BioChem 6, 27–32
2. Hinz, J. M. (2010) Role of homologous recombination in DNA interstrand
crosslink repair. Environ. Mol. Mutagen. 51, 582–603
3. Auerbach, A. D. (2009) Fanconi anemia and its diagnosis.Mutat. Res. 668,
4–10
4. Crossan, G. P., and Patel, K. J. (2012) The Fanconi anaemia pathway or-
chestrates incisions at sites of crosslinked DNA. J. Pathol. 226, 326–337
5. Zhang, J., and Walter, J. C. (2014) Mechanism and regulation of incisions
during DNA interstrand cross-link repair. DNA Repair 19, 135–142
6. Clauson, C., Schärer, O. D., and Niedernhofer, L. (2013) Advances in
understanding the complex mechanisms of DNA interstrand cross-link
repair. Cold Spring Harb. Perspect. Biol. 5, a012732
7. Liu, T., Ghosal, G., Yuan, J., Chen, J., and Huang, J. (2010) FAN1 acts with
FANCI-FANCD2 to promote DNA interstrand cross-link repair. Science
329, 693–696
8. Smogorzewska, A., Desetty, R., Saito, T. T., Schlabach, M., Lach, F. P.,
Sowa, M. E., Clark, A. B., Kunkel, T. A., Harper, J. W., Colaiácovo, M. P.,
and Elledge, S. J. (2010) A genetic screen identifies FAN1, a Fanconi ane-
mia-associated nuclease necessary for DNA interstrand crosslink repair.
Mol. Cell 39, 36–47
9. Kratz, K., Schöpf, B., Kaden, S., Sendoel, A., Eberhard, R., Lademann, C.,
Cannavó, E., Sartori, A. A., Hengartner, M. O., and Jiricny, J. (2010) Defi-
ciency of FANCD2-associated nuclease KIAA1018/FAN1 sensitizes cells
to interstrand crosslinking agents. Cell 142, 77–88
10. MacKay, C., Déclais, A. C., Lundin, C., Agostinho, A., Deans, A. J., Mac-
Artney, T. J., Hofmann, K., Gartner, A., West, S. C., Helleday, T., Lilley,
D. M., and Rouse, J. (2010) Identification of KIAA1018/FAN1, a DNA
repair nuclease recruited to DNA damage by monoubiquitinated
FANCD2. Cell 142, 65–76
11. Pennell, S., Déclais, A. C., Li, J., Haire, L. F., Berg, W., Saldanha, J. W.,
Taylor, I. A., Rouse, J., Lilley, D. M., and Smerdon, S. J. (2014) FAN1
activity on asymmetric repair intermediates is mediated by an atypical
monomeric virus-type replication-repair nuclease domain. Cell Rep. 8,
84–93
12. Munoz, I. M., Szyniarowski, P., Toth, R., Rouse, J., and Lachaud, C. (2014)
Improved genome editing in human cell lines using the CRISPR method.
PloS ONE 9, e109752
13. Yoshikiyo, K., Kratz, K., Hirota, K., Nishihara, K., Takata,M., Kurumizaka,
FAN1-catalyzed Unhooking of ICLs
22610 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290•NUMBER 37•SEPTEMBER 11, 2015
 at UZH Hauptbibliothek / Zentralbibliothek Zuerich on September 17, 2015
http://www.jbc.org/
Downloaded from 
2 Results  
 47 
H., Horimoto, S., Takeda, S., and Jiricny, J. (2010) KIAA1018/FAN1 nu-
clease protects cells against genomic instability induced by interstrand
cross-linking agents. Proc. Natl. Acad. Sci. U.S.A. 107, 21553–21557
14. Zhou,W., Otto, E. A., Cluckey, A., Airik, R., Hurd, T.W., Chaki, M., Diaz,
K., Lach, F. P., Bennett, G. R., Gee, H. Y., Ghosh, A. K., Natarajan, S.,
Thongthip, S., Veturi, U., Allen, S. J., Janssen, S., Ramaswami, G., Dixon, J.,
Burkhalter, F., Spoendlin, M., Moch, H., Mihatsch, M. J., Verine, J., Reade,
R., Soliman, H., Godin,M., Kiss, D., Monga, G., Mazzucco, G., Amann, K.,
Artunc, F., Newland, R. C.,Wiech, T., Zschiedrich, S., Huber, T. B., Friedl,
A., Slaats, G. G., Joles, J. A., Goldschmeding, R., Washburn, J., Giles, R. H.,
Levy, S., Smogorzewska, A., and Hildebrandt, F. (2012) FAN1 mutations
cause karyomegalic interstitial nephritis, linking chronic kidney failure to
defective DNA damage repair. Nat. Genet. 44, 910–915
15. Orans, J., McSweeney, E. A., Iyer, R. R., Hast, M. A., Hellinga, H. W.,
Modrich, P., and Beese, L. S. (2011) Structures of human exonuclease 1
DNA complexes suggest a unified mechanism for nuclease family. Cell
145, 212–223
16. Tsutakawa, S. E., Classen, S., Chapados, B. R., Arvai, A. S., Finger, L. D.,
Guenther, G., Tomlinson, C. G., Thompson, P., Sarker, A. H., Shen, B.,
Cooper, P. K., Grasby, J. A., and Tainer, J. A. (2011) Human flap endonu-
clease structures, DNA double-base flipping, and a unified understanding
of the FEN1 superfamily. Cell 145, 198–211
17. Tsutakawa, S. E., Lafrance-Vanasse, J., and Tainer, J. A. (2014) The cutting
edges in DNA repair, licensing, and fidelity: DNA and RNA repair nu-
cleases sculpt DNA to measure twice, cut once. DNA Repair 19, 95–107
18. Mukherjee, S., Guainazzi, A., and Schärer, O. D. (2014) Synthesis of struc-
turally diverse major groove DNA interstrand crosslinks using three dif-
ferent aldehyde precursors. Nucleic Acids Res. 42, 7429–7435
19. Guainazzi, A., Campbell, A. J., Angelov, T., Simmerling, C., and Schärer,
O. D. (2010) Synthesis and molecular modeling of a nitrogen mustard
DNA interstrand crosslink. Chemistry 16, 12100–12103
20. Angelov, T., Guainazzi, A., and Schärer, O. D. (2009) Generation of DNA
interstrand cross-links by post-synthetic reductive amination. Org. Lett.
11, 661–664
21. Bregenhorn, S., and Jiricny, J. (2014) Biochemical characterization of a
cancer-associated E109K missense variant of human exonuclease 1. Nu-
cleic Acids Res. 42, 7096–7103
22. Hanada, K., Budzowska, M., Davies, S. L., van Drunen, E., Onizawa, H.,
Beverloo, H. B., Maas, A., Essers, J., Hickson, I. D., and Kanaar, R. (2007)
The structure-specific endonucleaseMus81 contributes to replication re-
start by generating double-strand DNA breaks. Nat. Struct. Mol. Biol. 14,
1096–1104
23. Klein Douwel, D., Boonen, R. A., Long, D. T., Szypowska, A. A., Räschle,
M.,Walter, J. C., andKnipscheer, P. (2014) XPF-ERCC1 acts in unhooking
DNA interstrand crosslinks in cooperation with FANCD2 and FANCP/
SLX4.Mol. Cell 54, 460–471
24. Harrington, J. J., and Lieber, M. R. (1994) Functional domains within
FEN-1 and RAD2 define a family of structure-specific endonucleases: im-
plications for nucleotide excision repair. Genes Dev. 8, 1344–1355
25. Zhang, J., Dewar, J. M., Budzowska, M., Motnenko, A., Cohn, M. A., and
Walter, J. C. (2015) DNA interstrand cross-link repair requires replica-
tion-fork convergence. Nat. Struct. Mol. Biol. 22, 242–247
26. Hanada, K., Budzowska, M., Modesti, M., Maas, A., Wyman, C., Essers, J.,
and Kanaar, R. (2006) The structure-specific endonuclease Mus81-Eme1
promotes conversion of interstrand DNA crosslinks into double-strands
breaks. EMBO J. 25, 4921–4932
27. Nair, N., Castor, D., Macartney, T., and Rouse, J. (2014) Identification and
characterization of MUS81 point mutations that abolish interaction with
the SLX4 scaffold protein. DNA Repair 24, 131–137
28. Ward, I. M., and Chen, J. (2001) Histone H2AX is phosphorylated in an
ATR-dependent manner in response to replicational stress. J. Biol. Chem.
276, 47759–47762
29. Vassin, V.M., Anantha, R.W., Sokolova, E., Kanner, S., and Borowiec, J. A.
(2009) Human RPA phosphorylation by ATR stimulates DNA synthesis
and prevents ssDNA accumulation during DNA-replication stress. J. Cell
Sci. 122, 4070–4080
30. Petermann, E., Orta,M. L., Issaeva, N., Schultz, N., andHelleday, T. (2010)
Hydroxyurea-stalled replication forks become progressively inactivated
and require two different RAD51-mediated pathways for restart and re-
pair.Mol. Cell 37, 492–502
31. Chaudhury, I., Stroik, D. R., and Sobeck, A. (2014) FANCD2-controlled
chromatin access of the Fanconi-associated nuclease FAN1 is crucial for
the recovery of stalled replication forks.Mol. Cell. Biol. 34, 3939–3954
32. Gwon, G. H., Kim, Y., Liu, Y., Watson, A. T., Jo, A., Etheridge, T. J., Yuan,
F., Zhang, Y., Kim, Y., Carr, A. M., and Cho, Y. (2014) Crystal structure of
a Fanconi anemia-associated nuclease homolog bound to 5! flap DNA:
basis of interstrand cross-link repair by FAN1.Genes Dev. 28, 2276–2290
33. Wang, R., Persky, N. S., Yoo, B., Ouerfelli, O., Smogorzewska, A., Elledge,
S. J., and Pavletich, N. P. (2014) DNA repair. Mechanism of DNA inter-
strand cross-link processing by repair nuclease FAN1. Science 346,
1127–1130
34. Zhao, Q., Xue, X., Longerich, S., Sung, P., and Xiong, Y. (2014) Structural
insights into 5! flap DNA unwinding and incision by the human FAN1
dimer. Nat. Commun. 5, 5726
35. Fontebasso, Y., Etheridge, T. J., Oliver, A. W., Murray, J. M., and Carr,
A. M. (2013) The conserved Fanconi anemia nuclease Fan1 and the
SUMOE3 ligase Pli1 act in two novel Pso2-independent pathways ofDNA
interstrand crosslink repair in yeast. DNA Repair 12, 1011–1023
36. Wang, A. T., Sengerova, B., Cattell, E., Inagawa, T., Hartley, J. M., Kiakos,
K., Burgess-Brown, N. A., Swift, L. P., Enzlin, J. H., Schofield, C. J., Gileadi,
O., Hartley, J. A., and McHugh, P. J. (2011) Human SNM1A and XPF-
ERCC1 collaborate to initiate DNA interstrand cross-link repair. Genes
Dev. 25, 1859–1870
37. Muniandy, P. A., Liu, J., Majumdar, A., Liu, S. T., and Seidman, M. M.
(2010) DNA interstrand crosslink repair in mammalian cells: step by step.
Crit. Rev. Biochem. Mol. Biol. 45, 23–49
FAN1-catalyzed Unhooking of ICLs
SEPTEMBER 11, 2015•VOLUME 290•NUMBER 37 JOURNAL OF BIOLOGICAL CHEMISTRY 22611
 at UZH Hauptbibliothek / Zentralbibliothek Zuerich on September 17, 2015
http://www.jbc.org/
Downloaded from 
 
2 Results  
 48 
2.2 Additional Observations 
2.2.1 5' Flap cleavage activity in human TSCRE2 extracts 
FAN1 was the only one of the three tested endonucleases able to perform the unhooking 
reaction in vitro under the used conditions by cleaving 5' and 3' of the lesion. However, FEN1 
and EXO1 were also able to efficiently cleave the substrate 5' to the ICL, so we wondered 
what the relative contribution of these enzymes to ICL processing in cells might be. By using 
nuclear or whole cell extracts, we aimed to establish which nuclease has a higher propensity 
to cleave flap structures, either in general or in the vicinity of an ICL. The extracts should 
reflect the situation in the cell, with respect to the relative abundance of the different proteins, 
the presence of potential interaction partners and cofactors, and to a certain extent their 
relative activities. We used TSCRE2 cells, which are derivatives of the TK6 human 
lymphoblastoid cell line. They were either WT or knockout (KO) for FAN1, EXO1 or both. 
Using the 3' labeled substrates, we could show that the efficiency of endonucleolytic cleavage 
was not impaired in the nuclear extracts derived from any of the cell lines used (see Figure 
R1). This means that the major flap nuclease activity in the extracts is neither FAN1, nor 
EXO1. A good candidate for the protein performing the cleavage in the extracts could be 
FEN1, as no cleavages were made 3' to the ICL and the cross-link was only partially 
unhooked on the 5' side. This reflects FEN1 rather than FAN1 substrate specificity. A similar 
cleavage pattern was seen in nuclear extracts of WT HEK293 cells. As FEN1 deletion is lethal 
in human cells, we switched to the chicken DT40 cell line, where FEN1 KO is viable. 
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Figure R1: Nuclease assays with 
TSCER2 nuclear extracts on 5’ 
flap substrates with or without an 
ICL. Nuclear extracts from WT, 
FAN1, EXO1 and double KO 
TSCER2 cells were incubated with 
the depicted flap substrates, 
radioactively labeled at the 3’ end 
(orange star). The products were 
separated on a 20% denaturing 
polyacrylamide gel. The ICL is 
indicated by a red line in the 
drawing. HEK293 nuclear extracts 
were used as an additional control. 
The cleavage positions are indicated 
by arrows on the drawings (below 
for the non-cross-linked and on the 
right for the cross-linked substrates). 
The western blot (WB) shown below 
the DNA gel of WT, FAN1, EXO1, or 
double KO extracts confirms the 
absence of FAN1. TFIIH was used 
as a loading control. Marker: Low 
molecular weight marker 
(Affymetrix), oligonucleotide sizes 
are indicated on the left. 
  
2.2.2 FEN1 is responsible for almost all 5' flap cleavage in chicken cell extracts, 
but FAN1 activity becomes detectable upon overexpression 
As FEN1 KO is lethal in human cells but viable in DT40 chicken cells, we made use of FEN1 
KO cells in the DT40 system that were generated by Dr. Saho Kobayashi in our laboratory. To 
test whether FEN1 was really the major 5' flap endonuclease in the extracts, we performed in 
vitro nuclease assays on 5' flap DNA structures using extracts of WT, FAN1 KO or FEN1 KO 
DT40 cells. FAN1 KO cell extracts cleaved the substrate in a very similar way as the extracts 
derived from the WT cells, which was consistent with the results using the human TSCER2 
cell line extracts. FEN1 KO, on the other hand, almost completely lacked the main cleavage 
activity (Figure R2A). This means that FEN1 is indeed the most efficient 5' flap endonuclease 
present in extracts derived from these cells and that FAN1 (or any other endonuclease) 
activity is minimal under the used conditions. 
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Figure R2: Activity of Chicken DT40 extracts on 5’ flap structures. A) Extracts from WT, 
FAN1 KO, and FEN1 KO DT40 cells were used in nuclease assays. The 5’ flap substrate, as 
depicted, was labeled at the 5’ end (orange star). Marker and gel as in Figure R1. 
Oligonucleotide sizes are indicated on the left. B) The same type of assay as in A) was 
performed using extracts from FEN1 KO cells transfected with a plasmid expressing either 
chicken (g)FAN1 or human (h)FAN1. The numbers indicate different clones. The red arrow 
indicates the band corresponding to the cleavage position as shown on the schematic 
drawing on the right that appears specifically upon FAN1 overexpression.  
  
As FAN1 activity was very low in the extracts used for the nuclease assays, we aimed to see 
whether we could detect FAN1-dependent cleavage when overexpressing FAN1 in the 
chicken cells. To this end, we performed the same type of experiment using DT40 cells that 
contained a FAN1-expressing plasmid. Two clones overexpressing human FAN1 (hFAN1, 
#64 and #71) and two overexpressing chicken FAN1 (gFAN1, #12 and #29) were selected. 
As shown in Figure R2B, a weak 18-mer band appeared upon incubation of the DNA 
substrate with these extracts, as opposed to the 16-mer product generated in WT or FAN1 
KO extracts. Based on its size and on its presence solely in reactions using extracts of FAN1 
overexpressing cells, we concluded that FAN1 was the responsible endonuclease giving rise 
to this product. This means that FAN1 could potentially cleave also in the extracts, but that its 
abundance or activity is not high enough in WT extracts and therefore it is masked by FEN1 
activity. For efficient processing of DNA molecules by FAN1 in the cell, there have to be some 
regulatory mechanisms that keep FEN1 away and provide FAN1 with access to the correct 
DNA metabolic pathway. This regulation could be of any type, ranging from accessibility due 
to nuclear localization, post-translational modifications, cell-cycle dependent fluctuations, 
accessory proteins or cofactors etc. 
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 2.2.3 FEN1 depletion sensitizes chicken cells to MMC and this effect can be 
rescued by FAN1 overexpression 
This experiment was performed together with Dr. Saho Kobayashi. We have seen from the 
experiments listed above that FEN1 has the highest activity in the extracts under our 
experimental conditions. As FEN1 was also able to incise DNA 5' to an ICL at a model stalled 
replication fork (see chapter 2.1), we wondered whether it could also be involved in the 
unhooking step of ICL repair, or whether it is somehow actively kept away from these 
structures. As mentioned in the introduction, chapter 1.4, FEN1 needs to thread the free 5' 
end through a hole in its tertiary structure for flap recognition and efficient cleavage. This 
requirement would be somewhat contradictory to a function in ICL unhooking and the 
recovery of stalled replication forks, where no free 5' end is available. However, as also 
mentioned before, FEN1 has in addition to its 5' flap endonuclease also a gap endonuclease 
activity, which allows it to cleave at the base of a model stalled replication fork (152). This 
GEN activity could allow it to unhook ICLs by cleaving a replication fork stalled at an ICL. 
Indeed, FEN1 KO DT40 cells were hypersensitive to MMC compared to the WT cells (Figure 
R3A). The question then arose whether the sensitivity is specific to an unhooking function, as 
is expected for FAN1 or whether it is involved in a step other than the FAN1-dependent one. 
To address this question, we used the FEN1 KO DT40 cells overexpressing FAN1 to see 
whether this rescues the sensitivity, which would mean that the two endonucleases have the 
ability to cleave similar ICL-dependent substrates in the cell. Indeed, the overexpression of 
either chicken or human FAN1 in the FEN1 KO cells led to a rescue of sensitivity towards 
MMC (Figure R3A).  Clone number 29 for gFAN1 and clone number 64 for hFAN1 expressed 
higher GFP levels compared to clones 12 (gFAN1) and 71 (hFAN1) as seen in the FACS 
profiles (Figure R3B). Interestingly, the overexpression also correlated with the extent of 
resistance in the survival study, which indicates that FAN1 is most likely the responsible factor 
for the change in sensitivity. This could be explained by the fact that the activity and/ or 
abundance of FAN1 is quite low in the cells, as pointed out in the previous section, and that it 
is only able to perform a subset of incisions in the absence of FEN1, which has a partially 
redundant role. Upon overexpression of FAN1, however, there is enough enzyme to fully 
rescue the phenotype. We are currently generating the double KO cell line and, given that this 
is not lethal in DT40, would like to carry out a similar analysis on these cells, where we would 
expect a further decrease in survival compared to the single KO cell lines. 
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Figure R3: Sensitivity of chicken DT40 cells to MMC. A) Survival of FEN1 KO DT40 cells 
and two clones each overexpressing chicken (g, left graph) or human (h, right graph) FAN1 
compared to WT cells after MMC treatment at the indicated concentrations. Survival was 
assessed by colony formation in methylcellulose-containing medium. Numbers indicate the 
different clones. B) FACS profiles of the cells used in A). Counts (y-axis) are plotted against 
FITC log (x-axis) for the GFP signal that is expressed from the same vector as gFAN1 or in 
the same open reading frame as hFAN1.  
 
2.2.4 FAN1 protein levels in human cells are higher in the absence of FEN1 
protein 
As FEN1 seems to outcompete FAN1 under normal conditions, we wondered whether the two 
proteins could be alternatively regulated, i.e. whether FAN1 could become more abundant 
upon the loss of FEN1. Furthermore, we wanted to see whether the results obtained with the 
DT40 cell lines could also be relevant for human cells. First, we performed a clonogenic 
survival assay with U2OS cells treated with siRNA against FAN1, FEN1 or both proteins 
together (Figure R4A). As could be expected from the results in DT40 cells, the lack of both 
proteins led to a decrease in survival upon treatment with MMC and the co-depletion 
increased the effect further. This could indeed indicate that the two proteins act on a similar 
substrate in the process of ICL repair and that they could partially compensate for each 
other's loss. To see whether this compensation mechanism could even be visible on the 
protein or mRNA level, we prepared chromatin and whole cell extracts from U2OS cells and 
studied these levels upon depletion of one of the two proteins and after treatment with MMC. 
Whereas FEN1 expression or stability did not seem to be affected by the absence of FAN1 
(but was rather lower at mRNA level), FAN1 levels were slightly higher upon FEN1 KO both, 
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at the protein and mRNA levels (Figure R4B/C). Similar results were obtained for protein 
levels in HEK293 cells (Figure R4B). This is consistent with the previous results, showing 
that FAN1 could compensate for FEN1 loss and it might do so by overexpression or an 
increase in stability. Based on its high activity in extracts, it also makes sense that FEN1 
levels are not increased upon FAN1 downregulation, as it is probably already saturated under 
normal conditions. The increase of FAN1 mRNA levels upon FEN1 knockdown would have to 
be confirmed further, but if it is true, this could mean that the increase in intermediate DNA 
structures normally cleaved by FEN1 or FAN1 upon the loss of the former leads to a signaling 
cascade which ultimately triggers transcription of the FAN1 gene. The fact that the levels are 
increased in all, the chromatin, soluble and whole cell fractions indicates that this is not due to 
an increased recruitment or retention of proteins on the chromatin, but rather to a global 
response in stability or expression level. 
 
 
Figure R4: Human cells lacking FAN1, FEN1, or both. A) U2OS cells were treated with the 
indicated siRNAs and doses of MMC and survival was assessed by clonogenic survival 
assay. B) Western blot analysis of U2OS chromatin-enriched or soluble protein extracts or 
HEK293 whole cell extracts treated with the indicated siRNAs and MMC (1 µg/ml, 24 h). 
GAPDH was used as a loading control. C) mRNA levels as assessed by quantitative reverse-
transcription PCR of U2OS cells treated as indicated in B). 
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3 Discussion 
3.1 In vitro unhooking activity 
FAN1 has been proposed to be important for the process of ICL repair and was already 
shown to have both endo- and exonucleolytic activities in vitro. By using DNA substrates 
containing site-specific ICLs, I could show that FAN1 is able to make incisions both 5' and 3' 
of the lesion under the conditions used and that it proceeds in an exonucleolytic manner once 
it passed the site of the ICL. This was true for both 5' flapped as well as linear double-
stranded DNA, indicating that FAN1's ability to process DNA molecules containing a cross-
link is not dependent on its 5' flap endonuclease activity. FEN1 and EXO1, two other endo- 
and exonucleases were not able to perform a similar reaction; they were stalled by the 
presence of the cross-link and could not perform the unhooking reaction on both sides of it. 
Neither FEN1 nor EXO1 have been implicated in ICL repair so far and this would be in line 
with their inability to unhook cross-links in vitro. When looking at the crystal structures of 
FAN1, FEN1 and EXO1 bound to DNA, it is intriguing to note that FEN1 and EXO1 use a two-
nucleotide fraying mechanism to position the scissile phosphate at their active site (150,175). 
This means that the two terminal bps of the 5' flapped strand are unpaired to allow bending of 
the ssDNA towards the active site, divalent metal ion binding and cleavage. As such an 
unpairing mechanism is not possible if a cross-link is present at the base of the junction, it 
could explain why the FEN1 superfamily of endonucleases, to which both EXO1 and FEN1 
belong, are able to make the incision directly at the junction, but not further downstream. 
FAN1 on the other hand does not seem to involve such an unpairing and bending mechanism 
for recognition and cleavage and makes only relatively loose contacts with the phosphates of 
the second and third nucleotide after the junction within the DNA strand it is cleaving. This 
could explain its ability to process highly-distorted DNA structures (166). Only Zhao et al. 
proposed a substrate unwinding mechanism for FAN1 nuclease activity from their crystal 
structure, but this is in contrast to the other published FAN1 structures (169).  
Close examination of the biochemical activity of FAN1 reveals that its exonuclease activity is 
unusual, for example in comparison with EXO1. It is much more active at the entry point (as 
revealed by the strong bands on the gels) and loses its activity upon travelling away from the 
entry point. Furthermore, it seems to make stronger incisions at every third nucleotide. 
Together with the fact that it has only one active site, the mutation of which abolishes both 
activities, this indicates that the apparent exonuclease activity is rather a processive 
endonuclease cleaving always at a distance of 3 nucleotides from the entry site. FAN1 
endonuclease usually makes one major cut at the preferred cleavage site and one (or more) 
minor ones on each side of it, probably due to some flexibility in the active site. Thus, when 
looking at the degradation of the 3' labeled substrates, one observes an exonuclease-like 
pattern. This mode of action might also be the reason why FAN1 is not blocked by the 
presence of the ICL as opposed to EXO1 for example. A similar observation was made by 
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Wang et al., who showed that (truncated) hFAN1 has a relatively flexible active site leading to 
a ±1 nt shift in the scissile phosphate register (168). 
What these authors also provided was a direct proof of unhooking of a triazole ICL by 
analyzing the FAN1-generated products by LC-MS. They also demonstrated the need for a 5' 
phosphate that makes contacts with FAN1. Hence, shorter flaps were cleaved more efficiently 
than long ones. Furthermore, the addition of a 3' flap on the nicked strand enhanced activity. 
The nicked substrate without a 5' flap, or those with 1- or 2 nt flaps were cleaved efficiently 
under physiological salt conditions (150 mM), whereas longer flaps needed lower ionic 
strength. I observed efficient cleavage of all flap lengths used, although I have not used 
substrates described in their studies. Moreover, I always worked at low salt concentrations. It 
is unclear why changing the salt concentration results in such a shift in activity and substrate 
requirements, but given the fact that the cellular salt concentration is around 150 mM, it could 
be assumed that FAN1 in the cell has a more restricted substrate spectrum than what we see 
in vitro and that it actually prefers shorter flaps or even nicked substrates over long flaps.  
It would be interesting to see whether FAN1 possesses residues that affect its ability to 
process ICLs to a greater extent than undamaged substrates. Such a separation-of-function 
mutant would be a useful tool to study FAN1's functions in the cell within and outside of ICL 
repair. According to hFAN1's crystal structure, the 5' phosphate makes contacts with a highly 
basic pocket at the C-terminal domain of FAN1, while the next two phosphodiester groups 
make relatively few contacts and only the nonbridging oxygen atom of the third 
phosphodiester group coordinates the metal ion at the active site (168). This explains the 
cleavage by FAN1 in 3-nt spacings and might explain its ability to accomodate and cleave 
distorted and cross-linked DNA substrates. One way of creating a FAN1 version that would 
exclusively cleave unmodified DNA molecules would be by narrowing the active center 
around the second and third phosphodiester groups and tightening the contacts with them. 
This would have to be done by randomly mutating the residues around that region, as it is not 
easy to predict the effects of these mutations beforehand. 
3.2 In vivo implications of FAN1 unhooking activity 
DSB formation was decreased in the absence of FAN1 in U2OS cell lines upon treatment with 
MMC, which could argue in favor of a function in unhooking. However, the occurrence of 
these DSBs is not a direct proof of unhooking and it could be that they disappear because of 
a more efficient repair of the lesion in the absence of FAN1 (decreasing the intermediate 
DSBs faster). This is however unlikely because of the increase in DSBs over time (see Figure 
5B) and the notion that FAN1 depletion leads to slower DSB repair, as exemplified by the 
disappearance of foci of DSB repair markers such as RPA, RAD51 or γH2AX (158,159). It 
might seem contradictory that DSB induction is decreased upon FAN1 loss, but these 
markers persist longer. However, the type of damage was not strictly comparable, as the 
PFGE experiments were done with MMC, which means that the DSBs were induced 
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specifically as an intermediate step of ICL repair. The amount of MMC used was not 
compatible with survival, but it led to a high load of ICLs and repair intermediates, making the 
effects better visible. The DSBs seen by PFGE are not a direct sign of cell death or survival 
upon MMC treatment, as FAN1 depleted cells have a lower DSB load but are still more prone 
to die, as seen at lower MMC concentrations. Treating the cells with IR, on the other hand, led 
to the specific induction of DSBs, which might require the function of FAN1 in a different step, 
downstream of end resection.  
FAN1 was shown to be important for the recovery of stalled replication forks (164,176). The 
induction of FAN1/ICL-dependent DSBs could therefore also be related to such a function, 
where the replication fork is stalled in front of an ICL. In that case, the ICL would not 
necessarily be unhooked on both sides and the potential of FAN1 to bypass ICL-containing 
DNA would not be needed. Consequently, treating cells with other replication fork blocking 
agents should also lead to a decrease in DSBs upon FAN1 loss, which could be tested. 
It is interesting that MUS81 was also shown to induce DSBs after the induction of ICLs. It also 
has a role in the recovery of stalled replication forks by cleaving intermediate structures 
(24,177). MUS81-dependent breaks actually seem to come from a persistence of stalled forks 
in the absence of XPF-SNM1A-dependent ICL unhooking (58). Like FAN1, MUS81 depletion 
did not affect the ability of Xenopus egg extracts to repair ICLs in a replication-dependent 
way. It could therefore be that the two proteins act in a common pathway. Indeed, I could 
show by PFGE and survival assays that the concomitant loss of both proteins did not alter the 
effect seen if only one protein was depleted. This means that the two proteins are not 
redundant and might act in the same pathway that resolves ICL-stalled replication forks. 
In general, the cell biological studies of unhooking functions are lagging behind the 
biochemistry. To take these studies further, one should look more closely at redundancies 
between different potential ICL unhooking enzymes and other nucleases involved in ICL 
repair to take these studies further. Furthermore, ICL disappearance, for example with 
digoxigenin-tagged psoralen, could be used to study ICL unhooking enzymes (130). Another 
way of showing the unhooking of ICLs in cells would potentially be by performing 2-D gel 
analysis containing a native and a denaturing dimension on sheared chromosomal DNA so 
that hooked and unhooked DNA would run differently.  As mentioned, separation-of function 
mutants would be useful to test FAN1's role in unhooking, independently of its other roles. 
3.3 Evidence for FAN1 involvement in processes other than ICL 
unhooking 
In recent years it has become clear that FAN1 is a versatile protein, having functions in 
different DNA metabolic pathways. As it seems to be redundant with other nucleases in each 
of these functions, it has been difficult to study them.  
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The sensitivity of FAN1-depleted cells to ICL agents is not as pronounced as upon down-
regulation of other factors, such as FANC proteins. For its function in other DNA repair 
processes, no indicative sensitivity is observed. FAN1 depletion does not lead to 
hypersensitivity to CPT, for example, which induces a large amount of DSBs. The situation is 
similar when using replication fork stalling agents, such HU or APH. However, in specific 
assays, like the DR-GFP reporter assay to assess DSB repair, FAN1 depletion shows a mild 
phenotype (158,159). It could be that these assays are more sensitive and can detect minor 
changes in the phenotype, which are not observable by survival studies. This would mean 
that FAN1 has only minor functions in these pathways, maybe acting as a 'back-up' nuclease, 
which comes into play when the main nucleases responsible for the task are missing. 
Moreover, depending on the design of the reporter assays, there could already be some 
channeling into a specific repair pathway, leading to a certain bias in the results. 
3.3.1 Replication fork recovery 
FAN1 was proposed to act independently of the UBZ domain in ICL repair and to have a 
second, UBZ-dependent function in the recovery of stalled replication forks (176). Intriguingly, 
MEFs expressing a FAN1 variant with a mutated UBZ domain were not sensitive to any 
particular drug, but showed an increase in chromosomal aberrations upon treatment with HU 
or MMC. The authors correlate the UBZ-defective mutant phenotypes with those resulting 
from FANCD2 loss and therefore conclude that this interaction is responsible for the function 
in prevention of chromosomal instability. However, it is unclear why no sensitivity is detected 
upon the treatment with such agents, given the high amount of chromosomal abnormalities in 
these cells. It could be that the effects of the UBZ FAN1 mutant and FANCD2 deficiency are 
independent and that FAN1 actually depends on the presence of another (ubiquitinated) 
protein for recruitment. It would still work in a common pathway with FANCD2, as the two 
were shown to be epistatic, but the UBZ domain would actually be required for the binding to 
another protein. In fact, the authors did not show the direct interaction of FAN1 and FANCD2 
upon replication fork stalling. One interaction candidate could be PCNA, as this travels along 
with the replication fork and becomes ubiquitinated upon fork stalling. Furthermore, in a 
different publication, FAN1 was already shown to be required for the recovery of stalled 
replication forks upon APH treatment, but there this function was independent of the UBZ 
domain or the FA core complex (164).  
It is in general very difficult to differentiate between the functions of replication fork recovery 
and ICL unhooking, as an ICL is a special type of replication fork stalling agent and unhooking 
is essentially a special form of replication fork recovery.  
3.3.2 Homologous recombination 
FAN1 depletion was shown to decrease the efficiency of HR, but so far no further study was 
undertaken to pinpoint FAN1 to a particular step in HR (158,159). I previously tested the 
possibility of FAN1 being a HJ resolvase, even though such an activity is low in vitro. It could 
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however be that this is enhanced in vivo by specific regulation mechanisms. For this, I co-
depleted known HJ resolvases from HEK293 cells that contain the DR-GFP plasmid, allowing 
for HR scoring as a function of the fluorescence of the cells. None of the co-depleted proteins 
(GEN1, MUS81, XPF, SLX1 or MLH1) led to markedly lower HR efficiency compared to the 
single depletions, while RAD51 depletion, serving as a control, always showed a striking 
effect. Again, as is the case for replication fork stalling agents, FAN1 depletion does not 
sensitize cells to drugs or radiation that induce DSBs. It is highly probable therefore that 
another, redundant, protein fulfills a similar function, and the effect is only seen when using 
specific, more sensitive assays and not in overall cell survival. Due to the lack of additivity 
with other known HJ resolvases, it is unlikely that FAN1 has its main function in HJ resolution, 
although it cannot be excluded yet. Other potential substrates for FAN1 in the cell are D-
loops, as these were cleaved very efficiently in vitro, an activity that has been attributed also 
to the MUS81-EME2 (but not MUS81-EME1) complex (158,178). D-loop cleavage should 
however rather have an anti-recombinational effect in the cell, as it inhibits strand invasion 
and therefore further HR steps. Intriguingly, the MUS81-EME2 complex is also important for 
the recovery of stalled replication forks and its loss leads to an increase in chromosomal 
abnormalities, but it is not involved in the resolution of HJs, which is mediated by MUS81-
EME1 (179). Maybe we can learn from the studies that have been done with MUS81-EME2 
and test whether FAN1's function in HR and/or replication fork recovery is similar to the one of 
MUS81-EME2 or whether the two proteins act in completely different ways. MUS81-FAN1 co-
depletion should have given an increased effect in the DR-GFP reporter assay if they really 
act in a similar and partial redundant manner, but this could be tested again by specifically 
disrupting EME2. The two functions of FAN1 in stalled replication fork recovery and HR could 
actually be the same, as FAN1 might act in a pathway that recovers stalled replication forks in 
a recombination-dependent manner.  
3.4 FAN1 and FEN1 
We have tested the relative abundance and activities of FAN1 and FEN1 and looked for a 
potential link and redundancies between the two proteins. Although there is still a need for 
further experiments to draw final conclusions, it seems that the two proteins could act in a 
partially redundant fashion upon treating cells with MMC. FAN1 expression was slightly 
increased upon FEN1 loss both at the transcriptional and protein level, probably due to a 
higher load of specific repair intermediates. FEN1 has been shown to be able to resolve 
stalled replication forks involving its GEN activity and a specific interaction with WRN (152). 
Such an activity could also be used during ICL repair. Given that the ICL is more than 2 bps 
away from the junction, 5' flap cleavage could occur, as shown by my results. Such a cleaved 
structure could then further be used by FAN1 or SNM1A to perform the bypass reaction over 
the ICL.  
FEN1 is an essential protein and its deficiency is lethal in human cells and leads to a slow 
growth rate in DT40 chicken cells. Therefore, the possibility that the observed MMC sensiticity 
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is due to the general sickness of the cells rather than to the presence of the ICLs cannot be 
excluded. For example, the decreased growth rate, which includes slower replication, could 
hinder the replication-dependent ICL repair pathway, which could in turn lead to the higher 
sensitivity of the cells to this type of damage.  
3.5 FAN1 and SNM1A 
SNM1A is crucial during replication-dependent and -independent ICL repair, where its 
function was proposed to lie in the exonucleolytic degradation of the oligonucleotide around a 
cross-link.  
Interestingly, SNM1A seems to stop a short distance from the incision 3' to the ICL, possibly 
due to a steric inhibition of further exonucleolytic degradation by the remnant of the ICL 
(58,180). In contrast, the exonucleolytic activity of FAN1 is unaffected by the ICL. This could 
be explained by its +3 scissile phosphate register, which makes it possible to bypass the 
lesion (58). The recently identified crystal structure of SNM1A catalytic domain reveals a 
putative DNA-binding groove (180). Mutation of two lysine residues at one end of this groove 
(K904 and K906) led to a decreased processivity of the enzyme. Interestingly, the ability of 
SNM1A to digest past an ICL was affected to a greater extent than the activity on native DNA 
substrates. This points towards the importance of this groove to accommodate damaged and 
distorted DNA structures.  
SNM1A and FAN1 have both the ability to digest ICL-containing DNA, which seems to be a 
requirement for further lesion bypass by TLS pols. It could therefore be assumed that they 
have (partially) redundant functions in the cell. To test this, one could perform double 
depletion of the two proteins, where a stronger phenotype would be expected than upon the 
loss of the single proteins. Furthermore, it would be interesting to see under what 
circumstances one or the other protein comes into play and whether they have different 
propensities to process S-phase versus non S-phase dependent structures. As SNM1A has 
no endonucleolytic activity, it could also be that FAN1, or yet another nuclease, generates the 
first cut as an entry point for SNM1A, a function that has been proposed for XPF (58).  
3.6 Potential parallel pathways to repair ICLs 
It is likely that at least two different pathways to repair ICLs exist, a FA-dependent and a FA-
independent one. The question of course is, which pathway comes into play when and under 
what conditions. FAN1 seems to have a function in ICL repair that is independent of the FA 
pathway. FAN1 UBZ domain was dispensable for its function in ICL repair and thus the 
possibility of an alternative recruitment to sites of ICL damage exists (176). Also the fact that 
prokaryotic and lower eukaryotic FAN1 do not possess a UBZ domain means that this domain 
has evolved later for a more specific recruitment and higher specificity, but that certain 
functions can already be achieved by FAN1 independently of the UBZ domain. If FAN1 
function is independent of the FA core complex during the repair of ICLs, even though it 
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seems to be recruited in a monoubiquitinated FANCD2 (FANCD2-Ub)-dependent manner, the 
question arises why this specific recruitment happens at all. It could be that FAN1 could 
sense the damage and be recruited to it already by itself or by the interaction with a different 
(ubiquitinated or not) protein and that FANCD2-Ub somehow reinforces this interaction, but is 
not essential for its function there. Furthermore, it could be that this interaction is only 
required under certain conditions, for example in a specific cell cycle phase. To test this, the 
function of FAN1 outside of S-phase would have to be assessed. It is also possible that 
ubiquitin-independent interactions between FAN1 and FANCD2 exist. In line with that, Kratz 
et al. showed that the wild-type version of FAN1 was able to associate with both, unmodified 
FANCD2 and FANCD2-Ub, while the UBZ mutant only pulled-down the unmodified version. 
The results from the other primary papers do not all fully agree with this notion (157,159,160). 
Mutations in genes of the FA pathway lead to the severe genetic disorder Fanconi anemia, 
which predisposes affected individuals to cancers, like lymphoma and squamous cell 
carcinoma. FAN1 deficiency has, on the other hand, been associated with pancreatic and 
colon cancer and the kidney disease KIN, and its involvement in a FA-independent pathway 
could explain these discrepancies in symptoms (171,173,174). This means that one or the 
other pathway could be preferably used in certain tissues, cell cycle phases, or to repair 
different types of ICL damage based on their structures (171). The nuclease activity of 
different unhooking nucleases would have to be tested on a variety of ICLs to draw further 
conclusions about this point. Based on available evidence, XPF would be the preferred 
candidate for a FA-dependent nuclease (56).  
There are several possibilities how an ICL could be unhooked  by the known proteins. XPF 
could cleave 5' and 3' to the ICL if the replication fork is close to the ICL. Further processing 
could be performed by SNM1A or FAN1. SLX1, FEN1 or FAN1 could also provide an entry 
point 5' from the lesion at a stalled replication fork and MUS81 might cleave 3' to it, while 
FAN1 and SNM1A again could perform the degradation over the cross-link. In a replication-
independent situation, XPF could provide the entry point again for FAN1- or SNM1A-
dependent degradation. 
4 Conclusions and perspectives  
 61 
4 Conclusions and perspectives 
DNA repair mechanisms are essential to prevent genome instability and cancer. Despite the 
very fast accumulation of knowledge in this exiting field over the past decades, many details 
still remain unclear. The rapid growth of -omics data generated in high-throughput 
experiments permits the study of a variety of processes in the cell at once. Nevertheless, the 
thorough mechanistic understanding of the given processes is often fragmentary or lacking 
completely. In an attempt to learn more about FAN1-dependent processes in the cell, 
specifically about its role in ICL repair, I studied its ability to bypass such lesions in vitro. Even 
though it had become clear, also thanks to other studies, that FAN1 is able to perform such a 
bypass, we were still not able to unambiguously show that this function is also employed by 
the cell to repair this kind of damage. To show this, the easiest method would be to look at the 
disappearance of fluorescently tagged versions of ICLs in the presence or absence of FAN1. 
It would have to be designed in a way that the unhooked ICL no longer fluoresces and thus 
the actual release from one strand of the DNA could already be assessed. Other remaining 
questions are whether FAN1 only acts during S-phase or whether it could also have a G1-
specific function, and, of course, how this is regulated in the cell and which pathways are 
involved there. Specific ICL induction during G1 phase has already been achieved, using a 
psoralen analogue that can be fluorescently tagged by an antibody, and this method could be 
useful for the study of such a function (130). Of course one major question concerning FAN1 
still remains: the importance of the UBZ domain and whether this is used for the interaction 
with proteins other than FANCD2-Ub. Furthermore, it is still unclear if and how FAN1 can 
function in such diverse DNA metabolic pathways such as ICL repair, HR, stalled replication 
fork recovery, or MMR. One useful tool to study each of these functions would be separation-
of-function mutations or specific interaction site mutants that abolish the association with 
specific partners from each pathway. Such interaction partners could potentially be identified 
by pull-downs and mass spectrometry after treating cells with different types of drugs. Other 
nucleases can most likely complement at least some of FAN1's roles in each of these 
pathways. The different pathways are furthermore often related to each other and are not so 
easy to separate completely, which will make this study complicated and will undoubtedly 
keep many researchers from different laboratories busy for some time. Nevertheless, studying 
FAN1 in particular and DNA repair processes in general is an important task, as further 
knowledge in the field could potentially lead to improved cancer chemotherapy and decreased 
side-effects in patients.  
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5 Materials and Methods to section 2.2 
5.1 Substrates for endonuclease assays 
Substrate production was carried out as indicated in (181), using the oligonucleotides therein. 
5.2 Culturing of DT40 chicken cells 
Chicken B lymphocyte DT40 cells were cultured in RPMI-1640 medium (GIBCO), 
supplemented with 10% heat-inactivated Fetal Bovine Serum (GIBCO), 1% chicken serum 
(GIBCO), 10 µM β-Mercaptoethanol (GIBCO), 10000 U/ml penicillin and 10 mg/ml 
streptomycin (GIBCO) and kept at 39.5°C with 5% CO2. 
5.3 Culturing of TSCER2 cell lines and nuclear extract preparation 
Cells were kept in RPMI-1640 medium (GIBCO), supplemented with 5% heat-inactivated 
Fetal Bovine Serum (GIBCO), 18 mM Sodium Pyruvate (GIBCO), 10000 U/ml penicillin and 
10 mg/ml streptomycin (GIBCO) and at 37°C in 5% CO2. The Cas9-mediated knock-out cell 
lines were obtained and kindly provided by Dr. Shunsuke Kobayashi. Nuclear extracts of 
TSCER2 or HEK293 cells were made as described previously in (182).  
5.4 FAN1 overexpression in DT40 FEN1 KO cells 
The DT40 FEN1 KO cell lines were made by Dr. Saho Kobayashi as described in (156). 
FAN1 chicken cDNA was then cloned into the GFP-expressing vector pIRES2-EGFP also as 
described in (156). The human FAN1 cDNA was directly tagged with GFP, by using the 
pEGFP-C1 plasmid as described in (158). The expression plasmid was linearized with PvuI 
prior to transfection into DT40 cells. 30 µg of linear targeting vector were used for 
electroporating 5 x 106 cells using a Gene Pulser (BioRad) at 550 V, 25 µF. The cells were 
then transferred to a culture dish in 20 ml medium and incubated for 16 h at 39.5°C. 
Subsequently, selection medium was added containing 2 mg/ml Geneticin (G418, GIBCO) 
and the cells were plated on 96-well plates (200 µl/well). After around 7 days colonies started 
to appear and were transferred to 24-well plates. After further expansion the cells were 
analyzed by FACS (CyAn ADP9 Cytometer, Beckman Coulter) for the expression of GFP and 
stored for future experiments.  
5.5 Preparation of whole cell extracts from DT40 cells 
2 x 108 DT40 cells were grown in 200 ml of medium overnight, harvested, washed with cold 
PBS and resuspended in isotonic lysis [10 mM Tris-HCl, pH 7.5, 2 mM MgCl2, 3 mM CaCl2, 
0.32 M sucrose, 1/100 EDTA-free protease inhibitor cocktail (Roche), 1 mM Dithiothreitol 
(DTT), 0.1 mM Spermine, 0.5 mM Spermidine]. IGEPAL CA-630 (Sigma) was then added to a 
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final concentration of 0.3%, followed by immediate centrifugation at full speed. The 
supernatant was aliquoted for activity assays. 
5.6 Nuclease assays with DT40 extracts 
50 µg of DT40 extract were incubated with 50 fmol of radiolabeled DNA substrate in a volume 
of 25 µl and 1 x nuclease buffer [25 mM Hepes-KOH, pH 7.4, 1 mM MgCl2, 2.5% 
Polyethylenglycol (PEG), 0.5 mg/ml BSA, 30 mM DTT] for 30 min at room temperature. The 
reaction was stopped with 0.1% SDS, 14 mM EDTA, and 0.1 mg/ml Proteinase K for 15 min 
at 55°C. Loading buffer (80% formamide, 50 mM Tris-HCl pH 8, 1 mM EDTA) was added and 
the samples were separated on a 20% denaturing polyacrylamide gel containing 8 M Urea for 
1 hr at 40 V/cm. The gel was dried and the bands were visualized on a PhosphoImager 
(Typhoon FLA 9500, GE healthcare).  
5.7 Methylcellulose survival assay with DT40 cells 
DT40 medium, as specified above, was supplemented with 1.5% methylcellulose (Sigma) and 
mixed under constant stirring at 4°C. MMC was added one day prior to the assay at the 
indicated concentrations and the MMC-containing methylcellulose was stirred at 4°C again 
overnight. 100 to 3000 cells/ml were mixed with the methylcellulose-containing medium in 6-
well plates (35 mm diameter) depending on the expected survival and grown for one week 
before counting the colonies. 
5.8 quantitative real-time (RT) PCR 
qRT PCR was performed as described in (183). Primers used were the following: 
GAPDH forward:  AGG GCT GCT TTT AAC TCT GGT 
GAPDH reverse:  CCC CAC TTG ATT TTG GAG GGA 
FAN1 forward:   TGG CCC CAG GAA GAA GAA ATT 
FAN1 reverse:   GAT GTT CTG AGC AAT AAA ACA CAG GA 
FEN1 forward:   CTG TGG ACC TCA TCC AGA AGC A 
FEN1 reverse:   CCA GCA CCT CAG GTT CCA AGA 
SNM1A forward:  AAT CAC TGT CCA GGT GCT GTC AT 
SNM1A reverse:  TGG AAA GGT GTA TTC TGG GCT AC 
5.9 Antibodies 
Rabbit α-FEN1 (Bethyl laboratories, 1: 5000), mouse α-GAPDH (Millipore, 1:40'000), the 
remaining antibodies were as described in (181).  
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5.10 siRNAs 
siFEN1: UAAGUCCAUUGUUACAUGAAA. Other siRNAs and treatments as described in 
(181). 
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